ATE452975T1 - Immunoglobuline ohne leichte ketten - Google Patents

Immunoglobuline ohne leichte ketten

Info

Publication number: ATE452975T1
Authority: AT; Austria
Prior art keywords: immunoglobulins; light chains; antigen binding; polypeptide chains; immunoglobulin
Prior art date: 1992-08-21

Application number

AT05008358T

Other languages

English (en)

Inventor

Cecile Casterman

Raymond Hamers

Original Assignee

Univ Bruxelles

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-21

Filing date

1993-08-18

Publication date

2010-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26132410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE452975(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-08-21 Priority claimed from EP92402326A external-priority patent/EP0584421A1/de

1993-08-18 Application filed by Univ Bruxelles filed Critical Univ Bruxelles

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE452975T1 publication Critical patent/ATE452975T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT05008358T 1992-08-21 1993-08-18 Immunoglobuline ohne leichte ketten ATE452975T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP92402326A EP0584421A1 (de)	1992-08-21	1992-08-21	Immunoglobuline ohne Leichtkette
EP93401310		1993-05-21

Publications (1)

Publication Number	Publication Date
ATE452975T1 true ATE452975T1 (de)	2010-01-15

Family

ID=26132410

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
AT05008358T ATE452975T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichte ketten
AT04077639T ATE452207T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichte ketten
AT93919098T ATE203767T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichte ketten
AT00127968T ATE420178T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichtkette
AT05020889T ATE427968T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichtkette

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
AT04077639T ATE452207T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichte ketten
AT93919098T ATE203767T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichte ketten
AT00127968T ATE420178T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichtkette
AT05020889T ATE427968T1 (de)	1992-08-21	1993-08-18	Immunoglobuline ohne leichtkette

Country Status (13)

Country	Link
US (5)	US5840526A (de)
EP (6)	EP0656946B2 (de)
JP (4)	JP3444885B2 (de)
AT (5)	ATE452975T1 (de)
AU (1)	AU701578B2 (de)
CA (1)	CA2142331C (de)
DE (6)	DE69330523D1 (de)
DK (5)	DK1087013T3 (de)
ES (5)	ES2162823T5 (de)
FI (3)	FI115462B (de)
GR (1)	GR3037024T3 (de)
PT (5)	PT1498427E (de)
WO (1)	WO1994004678A1 (de)

Families Citing this family (1180)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6765087B1 (en) *	1992-08-21	2004-07-20	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
WO1994025591A1 (en) *	1993-04-29	1994-11-10	Unilever N.V.	PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP0739981A1 (de) *	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
US20040248201A1 (en) *	1996-06-27	2004-12-09	Serge Muyldermans	Recognition molecules interacting specifically with the active site or cleft of a target molecule
DK0937140T3 (da) *	1996-06-27	2008-01-28	Vlaams Interuniv Inst Biotech	Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
DK0931097T3 (da) *	1996-10-10	2006-01-16	Neose Technologies Inc	Kulhydratoprensning ved anvendelse af omvendt osmose og nanofiltrering
US20030228310A1 (en) *	1996-12-23	2003-12-11	Advanced Biotherapy, Inc.	Treatment of skin diseases
WO1999037681A2 (en) *	1998-01-26	1999-07-29	Unilever Plc	Method for producing antibody fragments
CA2327505A1 (en) *	1998-04-28	1999-11-04	Smithkline Beecham Corporation	Monoclonal antibodies with reduced immunogenicity
CA2370351A1 (en) *	1999-04-22	2000-11-02	Unilever Plc	Inhibition of viral infection using monovalent antigen-binding proteins
US6924359B1 (en) *	1999-07-01	2005-08-02	Yale University	Neovascular-targeted immunoconjugates
CA2379214A1 (en)	1999-07-27	2001-02-01	Unilever Plc	Bleaching detergent compositions
EP1212100B1 (de) *	1999-09-16	2005-04-06	Unilever Plc	Abgabesystem für ein mittel gegen schuppen
EP1088892A1 (de) *	1999-09-24	2001-04-04	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Rekombinante Phagen fähig zur eintritt in gastzellen durch verbindung mit kunstlichem rezeptor
US6479280B1 (en)	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ATE342922T1 (de)	1999-11-29	2006-11-15	Unilever Nv	Immobilisierung von proteinen mit hilfe eines polypeptidsegments
EP1118669A3 (de) *	1999-12-17	2001-08-29	Unilever Plc	Herstellung von Camelid-Antikörpern in Pflanzen
DE60138333D1 (de)	2000-03-14	2009-05-28	Unilever Nv	Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
US6696620B2 (en) *	2000-05-02	2004-02-24	Epicyte Pharmaceutical, Inc.	Immunoglobulin binding protein arrays in eukaryotic cells
CA2380443C (en)	2000-05-26	2013-03-12	Ginette Dubuc	Single-domain antigen-binding antibody fragments derived from llama antibodies
CA2441903C (en)	2000-05-26	2012-07-31	National Research Council Of Canada	Single-domain brain-targeting antibody fragments derived from llama antibodies
EP1340088B1 (de) *	2000-11-17	2007-01-17	University Of Rochester	In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US20050196755A1 (en) *	2000-11-17	2005-09-08	Maurice Zauderer	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20060064782A1 (en) *	2000-12-18	2006-03-23	Conopco, Inc.	Production of antibodies
BR0116283A (pt)	2000-12-19	2005-12-13	Unilever Nv	Grânulo de anticorpo, composições detergente, enzimática alvejante de manchas e enzimática de anti-transferência de corante, e, processo para a preparação de um grânulo de anticorpo
CA2447832C (en) *	2000-12-22	2012-09-25	Jamshid Tanha	Phage display libraries of human vh fragments
EP2198882A3 (de)	2001-01-12	2010-10-13	Novartis Vaccines and Diagnostics, Inc.	Nukleinsäure mukosale Immunisierung
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US20050069538A1 (en) *	2003-09-18	2005-03-31	Gregorio Aversa	Therapeutic binding molecules
US20040058445A1 (en) *	2001-04-26	2004-03-25	Ledbetter Jeffrey Alan	Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040062768A1 (en) *	2001-06-05	2004-04-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
US20040086508A1 (en) *	2001-06-05	2004-05-06	Advanced Biotherapy, Inc.	Treatment of organ transplant rejection
US6861056B2 (en) *	2001-06-05	2005-03-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
US20050152902A1 (en) *	2001-06-05	2005-07-14	Advanced Biotherapy, Inc.	Treatment of diabetic retinopathy
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
WO2003054016A2 (en) *	2001-12-21	2003-07-03	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Method for cloning of variable domain sequences
CA2471645A1 (en) *	2002-01-03	2003-07-10	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Immunoconjugates useful for treatment of tumours
AU2003205615B2 (en)	2002-01-10	2008-09-25	Universiteit Gent	A novel splice variant of MyD88 and uses thereof
WO2003068977A2 (de)	2002-02-10	2003-08-21	Apoxis Sa	Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
US20030219436A1 (en) *	2002-03-15	2003-11-27	Ledbetter Jeffrey A.	Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
DK1517921T3 (da) *	2002-06-28	2006-10-09	Domantis Ltd	Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
NZ611387A (en)	2002-07-15	2015-05-29	Univ Texas	Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
AU2003251238A1 (en)	2002-08-07	2004-02-25	Umc Utrecht Holding B.V.	Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US7425619B2 (en)	2002-08-14	2008-09-16	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
GB0219720D0 (en) *	2002-08-23	2002-10-02	Univ Aberdeen	Polypeptide
US20040052790A1 (en) *	2002-09-18	2004-03-18	Advanced Biotherapy, Inc.	Treatment of schizophrenia
AU2003286003B2 (en)	2002-11-08	2011-05-26	Ablynx N.V.	Stabilized single domain antibodies
WO2004041865A2 (en)	2002-11-08	2004-05-21	Ablynx N.V.	Stabilized single domain antibodies
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
GB0230203D0 (en) *	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
BRPI0406694B8 (pt)	2003-01-10	2021-05-25	Ablynx Nv	polipeptídios terapêutico, seus homólogos, seus fragmentos, que são usados nas modulações da agregação plaquetária
EP1437764A1 (de) *	2003-01-10	2004-07-14	S.O.I. Tec Silicon on Insulator Technologies S.A.	Anpassungsfähiges Substrat für Heteroepitaxie, heteroepitaktische Struktur und Verfahren zur Herstellung eines anpassungsfähigen Substrates
KR101224235B1 (ko)	2003-04-11	2013-01-25	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
DK1639011T3 (da)	2003-06-30	2009-02-16	Domantis Ltd	Pegylerede enkelt-domæne antistoffer (dAb)
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
EP3095793B1 (de)	2003-07-28	2020-03-25	Genentech, Inc.	Verringerung des protein-a-auslaugens während einer affinitätschromatografie
AU2004263896A1 (en)	2003-08-08	2005-02-17	Genenews Inc.	Osteoarthritis biomarkers and uses thereof
EP1687452A4 (de) *	2003-09-30	2008-08-06	Centocor Inc	Menschliche hinge core mimetibodies, zusammensetzungen, verfahren und verwendungen
AU2004288231A1 (en)	2003-11-05	2005-05-19	Palingen, Inc.	Enhanced B cell cytotoxicity of CDIM binding antibody
DK1687338T3 (da)	2003-11-07	2011-02-07	Ablynx Nv	Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
US7999071B2 (en)	2003-12-12	2011-08-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
WO2005105984A2 (en) *	2004-04-12	2005-11-10	The Trustees Of The University Of Pennsylvania	Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
EP1750759A4 (de) *	2004-06-04	2008-06-04	Genencor Int	Screeningverfahren unter verwendung von antikörper schweren ketten
US20050276807A1 (en) *	2004-06-15	2005-12-15	Advanced Biotherapy, Inc.	Treatment of acne
US20050276806A1 (en) *	2004-06-15	2005-12-15	Advanced Biotherapy, Inc.	Treatment of autism
GB2416768A (en) *	2004-07-22	2006-02-08	Univ Erasmus	Heavy chain immunoglobulin complexes
KR101422286B1 (ko)	2004-07-22	2014-07-23	에라스무스 유니버시티 메디컬 센터 로테르담	결합 분자
US20060177445A1 (en) *	2004-08-16	2006-08-10	Boris Skurkovich	Treatment of inflammatory skin diseases
US7563443B2 (en) *	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
RU2401842C2 (ru)	2004-10-08	2010-10-20	Домантис Лимитед	Антагонисты и способы их применения
US7462454B2 (en) *	2004-10-12	2008-12-09	Advanced Biotherapy, Inc.	Treatment of herpes
BRPI0518151A2 (pt) *	2004-10-13	2009-06-16	Ablynx Nv	polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US20060121042A1 (en)	2004-10-27	2006-06-08	Medimmune, Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2006205900B8 (en)	2005-01-14	2012-04-05	Ablynx N.V.	Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
CA2595682A1 (en) *	2005-01-31	2006-08-03	Ablynx N.V.	Method for generating variable domain sequences of heavy chain antibodies
CN101495498B (zh)	2005-02-07	2013-09-18	基因信息公司	轻度骨关节炎生物标志物及其用途
AU2006213686A1 (en)	2005-02-09	2006-08-17	Avi Bio Pharma, Inc.	Antisense composition and method for treating muscle atrophy
PT1863849E (pt)	2005-03-11	2011-05-10	Syngenta Ltd	Controlo de pragas de roedores
AU2006239315B2 (en)	2005-04-28	2012-03-01	Ventana Medical Systems, Inc.	Enzymes conjugated to antiobodies via a PEG heterobifuctional linker
JP2008541015A (ja) *	2005-04-28	2008-11-20	ベンタナ・メデイカル・システムズ・インコーポレーテツド	ナノ粒子コンジュゲート
MX363423B (es)	2005-05-18	2019-03-22	Ablynx Nv	Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
PT3415535T (pt)	2005-05-20	2021-02-02	Ablynx Nv	Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
DE102005023617A1 (de)	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
NI200800032A (es)	2005-07-25	2009-03-23		Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
PT1931710T (pt)	2005-08-31	2017-03-28	Merck Sharp & Dohme	Anticorpos anti-il-23 manipulados
CA2621086A1 (en)	2005-09-01	2007-03-08	Schering Corporation	Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
CA2623841C (en) *	2005-09-27	2019-03-12	National Research Council Of Canada	Methods of identifying agents capable of tmem30a mediated transmigration across the blood brain barrier (bbb)
AU2006297304B2 (en)	2005-09-29	2012-05-17	Medimmune, Llc	Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7526409B2 (en) *	2005-10-07	2009-04-28	Oracle International Corporation	Automatic performance statistical comparison between two periods
GB0521139D0 (en)	2005-10-18	2005-11-23	Univ Sheffield	Therapeutic agent
AU2006304883A1 (en)	2005-10-21	2007-04-26	Genenews Inc.	Method and apparatus for correlating levels of biomarker products with disease
GB0522460D0 (en) *	2005-11-03	2005-12-14	Prendergast Patrick T	Composition and method for the treatment of avian influenza
EP2963011B1 (de) *	2005-11-23	2018-05-09	Ventana Medical Systems, Inc.	Molekulares konjugat
US10183986B2 (en)	2005-12-15	2019-01-22	Industrial Technology Research Institute	Trimeric collagen scaffold antibodies
EP1983823A1 (de)	2006-01-17	2008-10-29	VIB vzw	Hemmer der prolyl-hydroxylase 1 für die behandlung von skelettmuskeldegeneration
AU2007209201A1 (en) *	2006-01-24	2007-08-02	Domantis Limited	Fusion proteins that contain natural junctions
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
US7504106B2 (en) *	2006-03-14	2009-03-17	Boris Skurkovich	Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
EP1999147A1 (de) *	2006-03-27	2008-12-10	Ablynx N.V.	Medizinisches verabreichungsgerät für therapeutische proteine auf der basis von einzeldomänantikörpern
MX2008013397A (es) *	2006-04-21	2009-03-27	Wyeth Corp	Analisis de perfilamiento de expresion diferencial de fenotipos de cultivo celular y usos de los mismos.
BRPI0711119A2 (pt)	2006-05-02	2011-08-30	Actogenix Nv	administração microbiana de peptìdeos intestinais associados à obesidade
CA2654317A1 (en)	2006-06-12	2007-12-21	Trubion Pharmaceuticals, Inc.	Single-chain multivalent binding proteins with effector function
EP2815764A1 (de)	2006-06-14	2014-12-24	Macrogenics, Inc.	Verfahren zur Behandlung von Autoimmunerkrankungen anhand von monoklonalen Antikörpern mit reduzierter Toxizität
ES2599319T3 (es)	2006-06-26	2017-02-01	Macrogenics, Inc.	Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
EP2495307B9 (de)	2006-07-13	2018-05-02	Wyeth LLC	Herstellung des Blutgerinnungsfaktors IX mit verbessertem Glykosylierungsmuster
TWI405771B (zh)	2006-08-28	2013-08-21	Kyowa Hakko Kirin Co Ltd	具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
WO2008044928A1 (en)	2006-10-10	2008-04-17	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Complement inhibition for improved nerve regeneration
GB0621513D0 (en)	2006-10-30	2006-12-06	Domantis Ltd	Novel polypeptides and uses thereof
ES2493166T3 (es)	2006-11-01	2014-09-11	Ventana Medical Systems, Inc.	Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
EP2092080A1 (de)	2006-11-07	2009-08-26	Vib Vzw	Diagnose und behandlung akuter t-zellen-lymphoblasten-leukämie
US8470332B2 (en)	2006-11-22	2013-06-25	Bristol-Myers Squibb Company	Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
WO2008068280A1 (en) *	2006-12-05	2008-06-12	Ablynx N.V.	Peptides capable of binding to serum proteins
AR064333A1 (es)	2006-12-14	2009-04-01	Schering Corp	Anticuerpo anti-tslp de diseno
CA2672965C (en)	2006-12-19	2018-02-06	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
AU2007336242B2 (en)	2006-12-19	2012-08-30	Ablynx N.V.	Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9023352B2 (en)	2007-02-20	2015-05-05	Tufts University	Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
CN101663319A (zh) *	2007-02-21	2010-03-03	埃博灵克斯股份有限公司	针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
US20100111966A1 (en)	2007-02-23	2010-05-06	Schering Corporation	Engineered anti-il-23p19 antibodies
AR065420A1 (es)	2007-02-23	2009-06-03	Schering Corp	Anticuerpos anti-il-23 p19 de ingenieria
CA2679381A1 (en)	2007-02-28	2008-09-04	Schering Corporation	Engineered anti-il-23r antibodies
US20100135998A1 (en)	2007-02-28	2010-06-03	Schering Corporation	Combination therapy for treatment of immune disorders
EP2115126B1 (de)	2007-03-02	2015-04-08	Wyeth LLC	Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
SI2308514T1 (sl)	2007-03-23	2013-09-30	To-Bbb Holding B.V.	Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
WO2008136694A1 (en)	2007-05-04	2008-11-13	Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa	Engineered rabbit antibody variable domains and uses thereof
EP3072525B1 (de)	2007-05-14	2018-01-31	AstraZeneca AB	Verfahren zur reduzierung des basophilen-spiegels
JP2010528285A (ja) *	2007-05-23	2010-08-19	ベンタナ・メデイカル・システムズ・インコーポレーテツド	免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
WO2008151081A1 (en)	2007-06-01	2008-12-11	Omt, Inc.	Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
WO2008157299A2 (en) *	2007-06-15	2008-12-24	Wyeth	Differential expression profiling analysis of cell culture phenotypes and uses thereof
US10214588B2 (en)	2007-07-03	2019-02-26	Ablynx N.V.	Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
JP2010533004A (ja)	2007-07-13	2010-10-21	バクアイピーベスローテンフェンノートシャップ	哺乳動物ＩｇＧと結合する単一ドメイン抗原結合タンパク質
US8329421B2 (en)	2007-07-13	2012-12-11	Ventana Medical Systems, Inc.	Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
EP3327132A3 (de)	2007-08-09	2018-07-18	Wyeth LLC	Verwendung von perfusion zur erhöhung der produktion von fed-batch-zellkulturen in bioreaktoren
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US8216571B2 (en)	2007-10-22	2012-07-10	Schering Corporation	Fully human anti-VEGF antibodies and methods of using
JP5514399B2 (ja) *	2007-11-02	2014-06-04	国立大学法人岡山大学	無機硫黄化合物加水分解酵素の製造方法
US20100254980A1 (en)	2007-11-02	2010-10-07	Novartis Ag	Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
EP2219671A4 (de)	2007-11-09	2011-02-09	Salk Inst For Biological Studi	Verwendung von tam-rezeptorinhibitoren als immu-enhancer und tam-aktivatoren als immunsuppressoren
JP2011504740A (ja) *	2007-11-27	2011-02-17	アブリンクスエン．ヴェー．	ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
JP5490714B2 (ja)	2007-11-28	2014-05-14	メディミューン，エルエルシー	タンパク質製剤
US20090186358A1 (en) *	2007-12-21	2009-07-23	Wyeth	Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
EP2594584B1 (de)	2008-01-31	2015-07-15	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Molekül bestehend aus einer gentechnisch veränderten konstanten Domäne eines Antikörpers
US20110091462A1 (en)	2008-03-05	2011-04-21	Ablynx N.V.	Novel antigen binding dimer-complexes, methods of making and uses thereof
US9908943B2 (en)	2008-04-03	2018-03-06	Vib Vzw	Single domain antibodies capable of modulating BACE activity
WO2009121948A2 (en)	2008-04-03	2009-10-08	Vib Vzw	Single domain antibodies capable of modulating bace activity
GB0809069D0 (en)	2008-05-19	2008-06-25	Univ Leuven Kath	Gene signatures
WO2009124931A2 (en)	2008-04-07	2009-10-15	Ablynx Nv	Amino acid sequences directed against the notch pathways and uses thereof
CN102099377A (zh)	2008-04-11	2011-06-15	新兴产品开发西雅图有限公司	Cd37免疫治疗剂及其与双功能化学治疗剂的联合
AU2009237662A1 (en)	2008-04-17	2009-10-22	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2274331B1 (de)	2008-05-02	2013-11-06	Novartis AG	Verbesserte bindemoleküle auf fibronectin-basis und ihre verwendung
CN102099373A (zh)	2008-05-22	2011-06-15	百时美施贵宝公司	基于纤连蛋白的多价支架结构域蛋白
DK2995925T3 (da)	2008-06-05	2022-02-21	Ventana Med Syst Inc	Sammensætning til histokemisk processering
GB2461546B (en) *	2008-07-02	2010-07-07	Argen X Bv	Antigen binding polypeptides
US8444976B2 (en)	2008-07-02	2013-05-21	Argen-X B.V.	Antigen binding polypeptides
PL2700651T3 (pl)	2008-07-18	2019-09-30	Bristol-Myers Squibb Company	Kompozycje jednowartościowe dla wiązania cd28 i sposoby stosowania
EP2313436B1 (de)	2008-07-22	2014-11-26	Ablynx N.V.	Gegen multitarget-scavenger-rezeptoren und polypeptide gerichtete aminosäuresequenzen
SG10201405377XA (en)	2008-08-05	2014-12-30	Novartis Ag	Compositions and methods for antibodies targeting complement protein c5
WO2010033913A1 (en) *	2008-09-22	2010-03-25	Icb International, Inc.	Antibodies, analogs and uses thereof
US20100136584A1 (en) *	2008-09-22	2010-06-03	Icb International, Inc.	Methods for using antibodies and analogs thereof
CA2739357A1 (en)	2008-09-23	2010-04-08	Wyeth Llc	Methods for predicting production of activating signals by cross-linked binding proteins
RU2481824C2 (ru)	2008-10-29	2013-05-20	Аблинкс Н.В	Препараты однодоменных антигенсвязывающих молекул
AU2009314311B2 (en)	2008-10-29	2013-01-10	Ablynx N.V.	Methods for purification of single domain antigen binding molecules
EP2370465B1 (de)	2008-12-19	2019-01-23	Ablynx N.V.	Genetische immunisierung zur herstellung von immunoglobulinen gegen zell-assoziierte antigene wie p2x7, cxcr7 oder cxcr4
JP5719309B2 (ja)	2008-12-19	2015-05-13	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	哺乳動物細胞培養用の栄養補助剤及び使用方法
ES2701649T3 (es)	2009-01-14	2019-02-25	Ablynx Nv	Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
US20100189919A1 (en) *	2009-01-27	2010-07-29	Xerox Corporation	Imaging System And Process Using Monoclonal Antibodies
EP2394159B1 (de)	2009-02-04	2018-09-26	Molecular Innovations	Tests für den nachweis von prorenin und darin verwendete antikörper
US10005830B2 (en)	2009-03-05	2018-06-26	Ablynx N.V.	Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2230515B1 (de)	2009-03-16	2014-12-17	Agilent Technologies, Inc.	Passivierung von Oberflächen nach Ligandenkupplung
WO2010111378A1 (en)	2009-03-24	2010-09-30	Wyeth Llc	Membrane evaporation for generating highly concentrated protein therapeutics
GB0905023D0 (en)	2009-03-24	2009-05-06	Univ Erasmus Medical Ct	Binding molecules
JP5647222B2 (ja)	2009-04-10	2014-12-24	アブリンクスエン．ヴェー．	Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
JP2012524524A (ja)	2009-04-27	2012-10-18	ノバルティスアーゲー	ＩＬ−１２レセプターβ１サブユニットに特異的な治療用抗体の組成物および使用方法
EA027071B1 (ru)	2009-04-27	2017-06-30	Новартис Аг	АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
CA2759370C (en)	2009-04-30	2020-02-11	Peter Schotte	Method for the production of domain antibodies
EP2432499A2 (de)	2009-05-20	2012-03-28	Schering Corporation	Modulation von pilr-rezeptoren zur behandlung mikrobieller infektionen
KR101852204B1 (ko)	2009-06-05	2018-04-26	아블린쓰 엔.브이.	기도 감염의 예방 및/또는 치료를 위한 일가, 이가 및 삼가 항 인간 호흡기 세포융합 바이러스 (ｈｒｓｖ) 나노바디 구조물
AU2010268690B2 (en)	2009-07-03	2011-11-10	Avipep Pty Ltd	Immuno-conjugates and methods for producing them
WO2011003622A1 (en)	2009-07-10	2011-01-13	Ablynx N.V.	Method for the production of variable domains
US20120230918A1 (en)	2009-07-28	2012-09-13	Hoffmann-La-Roche Inc.	Non-invasive in vivo optical imaging method
SG177689A1 (en)	2009-07-31	2012-02-28	Organon Nv	Fully human antibodies to btla
WO2011018421A1 (en)	2009-08-10	2011-02-17	Morphosys Ag	Novel screening strategies for the identification of binders
JP6294585B2 (ja)	2009-09-03	2018-03-20	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗ｇｉｔｒ抗体
WO2011027132A1 (en)	2009-09-03	2011-03-10	Cancer Research Technology Limited	Clec14a inhibitors
LT2805731T (lt)	2009-09-03	2019-02-11	Ablynx N.V.	Stabilios polipeptidų kompozicijos ir jų panaudojimas
WO2011029823A1 (en)	2009-09-09	2011-03-17	Novartis Ag	Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US20110195494A1 (en)	2009-10-02	2011-08-11	Boehringer Ingelheim International Gmbh	Dll4-binging molecules
UY32920A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US20110117113A1 (en)	2009-10-09	2011-05-19	Gerald Beste	Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011045079A1 (en)	2009-10-15	2011-04-21	Intercell Ag	Hepatitis b virus specific human antibodies
US9340605B2 (en)	2009-10-22	2016-05-17	Universiteit Twente	VHH for application in tissue repair, organ regeneration, organ replacement and tissue engineering
PL2490720T3 (pl)	2009-10-23	2020-08-24	Millennium Pharmaceuticals, Inc.	Cząsteczki przeciwciał anty-gcc oraz powiązane kompozycje i sposoby
US9139825B2 (en)	2009-10-30	2015-09-22	Novartis Ag	Universal fibronectin type III bottom-side binding domain libraries
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP3594356A1 (de)	2009-11-04	2020-01-15	Merck Sharp & Dohme Corp.	Hergestrllte antikoper gegen tslp
CN102640001A (zh)	2009-11-05	2012-08-15	诺瓦提斯公司	预测纤维化进展的生物标记物
WO2011064382A1 (en)	2009-11-30	2011-06-03	Ablynx N.V.	Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP2954779B1 (de)	2009-12-10	2019-02-06	Regeneron Pharmaceuticals, Inc.	Mäuse zur produktion von schwerkettigen antikörpern
US20110150885A1 (en)	2009-12-11	2011-06-23	Atyr Pharma, Inc.	Aminoacyl trna synthetases for modulating hematopoiesis
EP3309176A1 (de)	2009-12-14	2018-04-18	Ablynx N.V.	Immunoglobulin variable einzeldomänen-antikörper gegen ox40l, konstrukte und therapeutische verwendung
WO2011084357A1 (en)	2009-12-17	2011-07-14	Schering Corporation	Modulation of pilr to treat immune disorders
WO2011075786A1 (en)	2009-12-23	2011-06-30	Avipep Pty Ltd	Immuno-conjugates and methods for producing them 2
WO2011083140A1 (en)	2010-01-08	2011-07-14	Ablynx Nv	Immunoglobulin single variable domain directed against human cxcr4
TWI513466B (zh)	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑
CN102781959A (zh)	2010-02-05	2012-11-14	埃博灵克斯股份有限公司	能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
KR20120125357A (ko)	2010-02-10	2012-11-14	노파르티스 아게	근육 성장을 위한 방법 및 화합물
PL2533761T3 (pl)	2010-02-11	2019-09-30	Ablynx N.V.	Sposoby i kompozycje do wytwarzania aerozoli
US20130012916A1 (en)	2010-02-11	2013-01-10	Glide Pharmaceutical Technologies Limited	Delivery of immunoglobulin variable domains and constructs thereof
WO2011106583A1 (en)	2010-02-26	2011-09-01	Ventana Medical Systems, Inc.	Polytag probes
AR080446A1 (es)	2010-03-03	2012-04-11	Boehringer Ingelheim Int	Polipeptidos de union a a-beta (beta amiloide)
EP2553449A2 (de)	2010-03-26	2013-02-06	Westfälische Wilhelms-Universität Münster	Ersatztherapie für glucocorticoide
US8937164B2 (en)	2010-03-26	2015-01-20	Ablynx N.V.	Biological materials related to CXCR7
US9101674B2 (en)	2010-03-29	2015-08-11	Vib Vzw	Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en)	2010-03-29	2017-01-31	Vib Vzw	Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
JP6154317B2 (ja)	2010-04-06	2017-06-28	アフロサフエ・エン・フエー	農薬の特異的送達
GB201105584D0 (en)	2011-04-01	2011-05-18	Imp Innovations Ltd	Cancer methods
JP5822913B2 (ja)	2010-04-20	2015-11-25	ヴェンタナメディカルシステムズ，インク．	２色発色性インサイツハイブリダイゼーション
US8980253B2 (en)	2010-04-26	2015-03-17	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
JP6294074B2 (ja)	2010-04-27	2018-03-14	エータイアーファーマ，インコーポレイテッド	イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6008837B2 (ja)	2010-04-28	2016-10-19	エータイアーファーマ，インコーポレイテッド	アラニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP6008838B2 (ja)	2010-04-29	2016-10-19	エータイアーファーマ，インコーポレイテッド	アスパラギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
US9068177B2 (en)	2010-04-29	2015-06-30	Atyr Pharma, Inc	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
WO2011139907A2 (en)	2010-04-29	2011-11-10	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
PL2563813T3 (pl)	2010-04-30	2016-01-29	Alexion Pharma Inc	Przeciwciała anty-C5a i sposoby stosowania przeciwciał
CA2797977C (en)	2010-05-03	2019-08-20	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
US8961961B2 (en)	2010-05-03	2015-02-24	a Tyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
ES2668207T3 (es)	2010-05-03	2018-05-17	Atyr Pharma, Inc.	Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
EP2566499B1 (de)	2010-05-04	2017-01-25	aTyr Pharma, Inc.	Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
EP2566967B1 (de)	2010-05-04	2016-07-06	The Brigham and Women's Hospital, Inc.	Cadherin-11-antagonisten zur behandlung von fibrose
US8877188B2 (en)	2010-05-04	2014-11-04	The Brigham And Women's Hospital, Inc.	Detection and treatment of non-dermal fibrosis
SG185415A1 (en)	2010-05-06	2012-12-28	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
KR20130066632A (ko)	2010-05-06	2013-06-20	노파르티스 아게	치료적 저밀도 지단백질-관련 단백질 ６（ｌｒｐ６） 항체에 대한 조성물 및 사용 방법
BR112012028006A2 (pt)	2010-05-07	2016-08-02	Hoffmann La Roche	método de imuno-histoquímica (ihq), uso de um domínio de ligação, kit e domínio de ligação terapeuticamente ativo
CA2799197C (en)	2010-05-14	2019-10-29	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN102906118B (zh)	2010-05-20	2017-07-28	埃博灵克斯股份有限公司	与her3相关的生物材料
CA2803588A1 (en)	2010-06-22	2011-12-29	The Regents Of The University Of Colorado, A Body Corporate	Antibodies to the c3d fragment of complement component 3
WO2011161263A1 (en)	2010-06-25	2011-12-29	Ablynx Nv	Pharmaceutical compositions for cutaneous administration
CA2805548A1 (en)	2010-07-02	2012-01-05	Vib Vzw	The role of fragile x mental retardation gene and protein in cancer metastasis
US20130109019A1 (en)	2010-07-02	2013-05-02	Adrian E. Murillo	Hapten conjugates for target detection
JP6116479B2 (ja)	2010-07-12	2017-04-19	エータイアーファーマ，インコーポレイテッド	グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP2013536175A (ja)	2010-07-16	2013-09-19	アブリンクスエン．ヴェー．	修飾された単一ドメイン抗原結合分子及びその使用
GB201014715D0 (en)	2010-09-06	2010-10-20	Vib Vzw	Nanobodies stabilizing functional conformational states of GPCRS
GB201012845D0 (en)	2010-07-30	2010-09-15	Vib Vzw	Inhibition of dicer function for treatment of cancer
AU2011285919C1 (en)	2010-08-02	2015-09-17	Regeneron Pharmaceuticals, Inc.	Mice that make binding proteins comprising VL domains
WO2012024185A1 (en)	2010-08-16	2012-02-23	Ventana Medical Systems, Inc.	Substrates for chromogenic detection and methods of use in detection assays and kits
US20130150554A1 (en)	2010-08-20	2013-06-13	Wyeth Llc	Cell culture of growth factor-free adapted cells
UA114883C2 (uk)	2010-08-20	2017-08-28	Новартіс Аг	Антитіло до рецептора епідермального фактора росту-3 (her3)
WO2012027611A2 (en)	2010-08-25	2012-03-01	Atyr Pharma, Inc.	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
US9380781B2 (en)	2010-08-26	2016-07-05	Agrosavfe N.V.	Compositions for seed treatment
US20130224226A1 (en)	2010-08-26	2013-08-29	Agrosavfe N.V.	Insect binding antibodies
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012042026A1 (en)	2010-09-30	2012-04-05	Ablynx Nv	Biological materials related to c-met
WO2012045703A1 (en)	2010-10-05	2012-04-12	Novartis Ag	Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
US20130261288A1 (en)	2010-10-29	2013-10-03	Ablynx N.V.	Method for the production of immunoglobulin single variable domains
GB201018602D0 (en)	2010-11-04	2010-12-22	Vib Vzw	MMP8 inactivating antigen binding proteins
CN103687618A (zh)	2010-11-05	2014-03-26	莫福特克公司	叶酸受体α作为用于表达叶酸受体α的癌症的诊断和预后标记
KR101650995B1 (ko)	2010-11-08	2016-08-25	노파르티스 아게	Ｃｘｃｒ２ 결합 폴리펩티드
WO2012084895A2 (en)	2010-12-20	2012-06-28	Universiteit Gent	Crystal structure of flt3 ligand-receptor complex
CA2817374C (en)	2010-12-30	2018-10-16	Ventana Medical Systems, Inc.	Enhanced deposition of chromogens utilizing pyrimidine analogs
WO2012089814A1 (en)	2010-12-30	2012-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigen binding formats for use in therapeutic treatments or diagnostic assays
EP2668210B1 (de)	2011-01-26	2020-06-17	Celldex Therapeutics, Inc.	Anti-kit-antikörper und ihre verwendungen
WO2012105833A1 (en)	2011-02-01	2012-08-09	Bac Ip B.V.	Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies
AR085141A1 (es)	2011-02-03	2013-09-11	Alexion Pharma Inc	Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
JP6385060B2 (ja)	2011-03-07	2018-09-05	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	治療的に活性な抗体のインビボにおける選択
EP2683290B1 (de)	2011-03-07	2018-11-07	F.Hoffmann-La Roche Ag	Verfahren zum in-vivo-testen von therapeutischen antikörpern
WO2012123387A1 (en)	2011-03-14	2012-09-20	F. Hoffmann-La Roche Ag	A method of analyzing chromosomal translocations and a system therefore
US9624294B2 (en)	2011-03-14	2017-04-18	Cellmid Limited	Antibody recognizing N-domain of midkine
DK2691415T3 (en)	2011-03-28	2018-10-29	Ablynx Nv	PROCEDURE FOR PREPARING SOLID FORMULATIONS CONTAINING VARIABLE SINGLE DOMAINS OF IMMUNOGLOBULIN
JP6181040B2 (ja)	2011-03-28	2017-08-16	アブリンクスエン．ヴェー．	二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
CN106039306A (zh)	2011-03-30	2016-10-26	埃博灵克斯股份有限公司	使用针对TNFα的单结构域抗体治疗免疫病症的方法
WO2012130834A1 (en)	2011-03-30	2012-10-04	Boehringer Ingelheim International Gmbh	Anticoagulant antidotes
JP6014116B2 (ja)	2011-03-31	2016-10-25	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
JP6072771B2 (ja)	2011-04-20	2017-02-01	メディミューン，エルエルシー	Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3590950A1 (de)	2011-05-09	2020-01-08	Ablynx NV	Verfahren zur herstellung von einzelvariablen immunglobulindomänen
CN107936121B (zh)	2011-05-16	2022-01-14	埃泰美德(香港)有限公司	多特异性fab融合蛋白及其使用方法
CA2835340A1 (en)	2011-05-27	2012-12-06	Ablynx Nv	Inhibition of bone resorption with rankl binding peptides
WO2012166906A1 (en)	2011-05-31	2012-12-06	Massachusetts Institute Of Technology	Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
US9193793B2 (en)	2011-06-13	2015-11-24	Csl Limited	Antibodies against G-CSFR and uses thereof
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
JP6164535B2 (ja)	2011-06-21	2017-07-19	フエー・イー・ベー・フエー・ゼツト・ウエー	Ｇｐｃｒ：ｇタンパク質複合体に対して作製された結合ドメインおよびそれに由来する使用
EP2723772A1 (de)	2011-06-23	2014-04-30	Ablynx N.V.	Gegen ige gerichtete variable immunglobulin-einzeldomänen
PT2723771T (pt)	2011-06-23	2019-12-11	Ablynx Nv	Proteínas de ligação à albumina sérica
JP6472999B2 (ja)	2011-07-01	2019-02-20	ノバルティスアーゲー	代謝障害を治療するための方法
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
WO2013010955A1 (en)	2011-07-15	2013-01-24	Morphosys Ag	Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
BR112014003679B1 (pt)	2011-08-17	2022-08-30	Glaxo Group Limited	Domínio variável de imunoglobulina único, composição farmacêutica, formulação, ácido nucleico isolado ou recombinante, vetor, microorganismo transgênico, e, uso de uma composição farmacêutica
WO2013033073A1 (en)	2011-08-31	2013-03-07	Ventana Medical Systems, Inc.	Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
GB201115529D0 (en)	2011-09-08	2011-10-26	Imp Innovations Ltd	Antibodies, uses and methods
EP2753644A1 (de)	2011-09-09	2014-07-16	Universiteit Utrecht Holding B.V.	Breit neutralisierende vhh gegen hiv-1
EP3128009B1 (de)	2011-09-19	2020-07-29	Kymab Limited	Massgeschneiderte antikörper, variable domänen und ketten für menschliche verwendung
WO2013041901A1 (en)	2011-09-20	2013-03-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing single domain antibody microarrays
EP2747782B1 (de)	2011-09-23	2018-01-17	Ablynx NV	Verlängerte inhibition der interleukin-6-vermittelten signalisierung
WO2013045916A1 (en)	2011-09-26	2013-04-04	Kymab Limited	Chimaeric surrogate light chains (slc) comprising human vpreb
EP2747783B1 (de)	2011-09-30	2017-06-14	Ablynx N.V.	Biologische stoffe im zusammenhang mit c-met
US20130085139A1 (en)	2011-10-04	2013-04-04	Royal Holloway And Bedford New College	Oligomers
US9296826B2 (en)	2011-10-14	2016-03-29	Novartis Ag	Antibodies and methods for WNT pathway-related diseases
US9127056B2 (en)	2011-10-17	2015-09-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
GB2496375A (en)	2011-10-28	2013-05-15	Kymab Ltd	A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9265817B2 (en)	2011-10-28	2016-02-23	Patrys Limited	PAT-LM1 epitopes and methods for using same
US9803004B2 (en)	2011-11-11	2017-10-31	Ucb Biopharma Sprl	Albumin binding antibodies and binding fragments thereof
WO2013079606A1 (en)	2011-12-01	2013-06-06	Ventana Medical Systems, Inc.	Automated dual stain of mirna and protein targets
GB201122047D0 (en)	2011-12-21	2012-02-01	Kymab Ltd	Transgenic animals
WO2013079973A1 (en)	2011-12-02	2013-06-06	Di Cara Danielle Marie	Antibodies against hgf - receptor and uses
US9192663B2 (en)	2011-12-05	2015-11-24	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3)
SG11201402739YA (en)	2011-12-05	2014-06-27	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
BR112014015111A2 (pt)	2011-12-21	2017-06-13	Novartis Ag	composições e processos para anticorpos que se direcionam ao fator p
US10112987B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
WO2013108126A2 (en)	2012-01-16	2013-07-25	University Of Oslo	Methyltransferases and uses thereof
CN104507967B (zh)	2012-01-20	2018-10-12	建新公司	抗cxcr3抗体
EP2809800A1 (de)	2012-01-30	2014-12-10	VIB vzw	Mittel und verfahren zur diagnose und behandlung von morbus alzheimer
WO2013121042A1 (en)	2012-02-16	2013-08-22	Vib Vzw	PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
UA115781C2 (uk)	2012-02-27	2017-12-26	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cx3cr1-зв'язуючий поліпептид
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
JP6101782B2 (ja)	2012-03-27	2017-03-22	ヴェンタナメディカルシステムズ，インク．	シグナリングコンジュゲート及び使用法
RS58732B1 (sr)	2012-03-30	2019-06-28	Boehringer Ingelheim Int	Ang2 vezujući molekuli
US9156915B2 (en)	2012-04-26	2015-10-13	Thomas Jefferson University	Anti-GCC antibody molecules
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
AU2013265665B2 (en)	2012-05-24	2017-10-26	Vib Vzw	Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
EP2687595B1 (de)	2012-07-19	2018-05-30	Laboratoire Français du Fractionnement et des Biotechnologies	Verfahren zur Reinigung eines transgenen Faktor VII
DK2877493T3 (en)	2012-07-25	2018-06-14	Celldex Therapeutics Inc	ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF
EP3184121A3 (de)	2012-07-25	2017-09-27	Salk Institute For Biological Studies	Regelung der interaktion zwischen tam-liganden und lipidmembranen mit exponiertem phosphatidylserin
WO2014035474A1 (en)	2012-08-30	2014-03-06	The General Hospital Corporation	Compositions and methods for treating cancer
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
KR20210063443A (ko)	2012-10-09	2021-06-01	바이오젠 엠에이 인코포레이티드	탈수초성 질환의 치료를 위한 복합 요법 및 용도
LT2922962T (lt)	2012-11-20	2017-04-10	Novartis Ag	Optimizuota raiškos kasetė, skirta polipeptido raiškai su didele išeiga
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
SG11201503567SA (en)	2012-12-05	2015-06-29	Novartis Ag	Compositions and methods for antibodies targeting epo
WO2014087010A1 (en)	2012-12-07	2014-06-12	Ablynx N.V.	IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
HRP20201160T4 (hr)	2012-12-14	2024-10-11	Open Monoclonal Technology, Inc.	Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
CN104995303A (zh)	2012-12-18	2015-10-21	诺华股份有限公司	利用结合乙酰透明质酸的肽标签的组合物和方法
AU2013361231A1 (en)	2012-12-19	2015-06-04	Amplimmune, Inc.	B7-H4 specific antibodies, and compositions and methods of use thereof
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
AR093984A1 (es)	2012-12-21	2015-07-01	Merck Sharp & Dohme	Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
BR112015014621A2 (pt)	2012-12-21	2017-10-03	Amplimmune Inc	Anticorpos anti-h7cr
WO2014118297A1 (en)	2013-01-30	2014-08-07	Vib Vzw	Novel chimeric polypeptides for screening and drug discovery purposes
WO2014120916A1 (en)	2013-02-01	2014-08-07	Bristol-Myers Squibb Company	Pegylated domain antibodies monovalent for cd28 binding and methods of use
PT2953973T (pt)	2013-02-05	2019-10-25	Univ Brussel Vrije	Agentes de ligação do receptor muscarínico de acetilololina e usos
CN104995211B (zh)	2013-02-07	2019-09-13	Csl有限公司	Il-11r结合蛋白及其应用
SG11201505330QA (en)	2013-02-08	2015-08-28	Novartis Ag	Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
WO2015198217A2 (en)	2013-02-08	2015-12-30	Novartis Ag	Compositions and methods for long-acting antibodies targeting il-17
CN110845618A (zh)	2013-02-26	2020-02-28	罗切格利卡特公司	双特异性t细胞活化抗原结合分子
WO2014133855A1 (en)	2013-02-28	2014-09-04	Caprion Proteomics Inc.	Tuberculosis biomarkers and uses thereof
AU2013381730B2 (en)	2013-03-12	2017-07-27	Ventana Medical Systems, Inc.	Digitally enhanced microscopy for multiplexed histology
CA2902026C (en)	2013-03-13	2023-08-29	Prothena Biosciences Limited	Tau immunotherapy
EP2970479B1 (de)	2013-03-14	2019-04-24	Novartis AG	Antikörper gegen notch 3
US10160797B2 (en)	2013-03-15	2018-12-25	Sanofi Pasteur Biologics, Llc	Antibodies against Clostridium difficile toxins and methods of using the same
EP2970372B1 (de)	2013-03-15	2020-09-30	Celgene Corporation	Modifizierte t-lymphozyten
EP3623380A1 (de)	2013-03-15	2020-03-18	Michael C. Milone	Targeting von zytotoxischen zellen mit chimären rezeptoren zur adoptiven immuntherapie
US10993420B2 (en)	2013-03-15	2021-05-04	Erasmus University Medical Center	Production of heavy chain only antibodies in transgenic mammals
JP6499090B2 (ja)	2013-03-15	2019-04-10	ブイアイビーブイゼットダブリュＶｉｂＶｚｗ	心血管疾患において使用するための抗マクロファージマンノース受容体単一可変ドメイン
JP6574754B2 (ja)	2013-03-19	2019-09-11	ベイジンシェノゲンファーマグループリミテッド	エストロゲン受容体関連疾患を処置するための抗体及び方法
WO2014177595A1 (en)	2013-04-29	2014-11-06	Agrosavfe N.V.	Agrochemical compositions comprising antibodies binding to sphingolipids
EP3583950A1 (de)	2013-05-09	2019-12-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
NL1040254C2 (en)	2013-05-17	2014-11-24	Ablynx Nv	Stable formulations of immunoglobulin single variable domains and uses thereof.
BR112015029395A2 (pt)	2013-05-24	2017-09-19	Medimmune Llc	Anticorpos anti-b7-h5 e seus usos
WO2014194293A1 (en)	2013-05-30	2014-12-04	Amplimmune, Inc.	Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
NZ714765A (en)	2013-06-06	2021-12-24	Pf Medicament	Anti-c10orf54 antibodies and uses thereof
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en)	2013-06-21	2017-02-07	Novartis Ag	Lectin-like oxidized LDL receptor 1 antibodies and methods of use
WO2014207173A1 (en)	2013-06-27	2014-12-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
US20160176943A1 (en)	2013-07-05	2016-06-23	Inserm (Insititut National De La Sante Et De La Recherche Medicale)	Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
WO2015004633A1 (en)	2013-07-12	2015-01-15	Neotope Biosciences Limited	Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015004632A1 (en)	2013-07-12	2015-01-15	Neotope Biosciences Limited	Antibodies that recognize iapp
EP4300103A3 (de)	2013-08-07	2024-02-28	Alexion Pharmaceuticals, Inc.	Biomarkerproteine für das atypische hämolytische urämische syndrom (ahus)
WO2015022658A2 (en)	2013-08-14	2015-02-19	Novartis Ag	Methods of treating sporadic inclusion body myositis
AR097306A1 (es)	2013-08-20	2016-03-02	Merck Sharp & Dohme	Modulación de la inmunidad tumoral
CN105873608A (zh)	2013-11-28	2016-08-17	杰特有限公司	治疗肾病的方法
EP2883883A1 (de)	2013-12-16	2015-06-17	Cardio3 Biosciences S.A.	Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
KR102466794B1 (ko)	2013-12-18	2022-11-11	씨에스엘 리미티드	상처 치료 방법
JP6779785B2 (ja)	2013-12-19	2020-11-04	ノバルティスアーゲー	ヒトメソテリンキメラ抗原受容体およびその使用
EP4420663A3 (de)	2013-12-20	2024-10-30	Novartis AG	Regulierbarer chimärer antigenrezeptor
RU2761663C2 (ru)	2013-12-20	2021-12-13	Интервет Интернэшнл Б.В.	Антитела к pd-1 собак
WO2015100409A2 (en)	2013-12-26	2015-07-02	Tufts University	Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JP6687525B2 (ja)	2014-01-30	2020-04-22	ブイアイビーブイゼットダブリュＶｉｂＶｚｗ	オピオイド受容体結合剤およびその使用
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2900749T3 (es)	2014-02-11	2022-03-18	Visterra Inc	Moléculas de anticuerpos contra el virus del dengue y usos de las mismas
US10675352B2 (en)	2014-02-14	2020-06-09	Centrose, Llc	Extracellular targeted drug conjugates
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
NZ631007A (en)	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
UY36032A (es)	2014-03-14	2015-10-30	Novartis Ag	Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
JP2017513818A (ja)	2014-03-15	2017-06-01	ノバルティスアーゲー	キメラ抗原受容体を使用する癌の処置
WO2015142661A1 (en)	2014-03-15	2015-09-24	Novartis Ag	Regulatable chimeric antigen receptor
WO2015143406A2 (en)	2014-03-21	2015-09-24	Regeneron Pharmaceuticals, Inc.	Vl antigen binding proteins exhibiting distinct binding characteristics
AU2015230938C1 (en)	2014-03-21	2021-10-14	Regeneron Pharmaceuticals, Inc.	Non-human animals that make single domain binding proteins
CA2944402A1 (en)	2014-04-08	2015-10-15	Prothena Biosciences Limited	Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
LT3134095T (lt)	2014-04-25	2020-06-10	Bluebird Bio, Inc.	Patobulinti adaptyviųjų ląstelių gydymo priemonės gamybos būdai
RS62733B1 (sr)	2014-04-25	2022-01-31	2Seventy Bio Inc	Mnd promoter himernih antigenskih receptora
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
HUE058008T2 (hu)	2014-05-16	2022-06-28	Ablynx Nv	Immunglobulin variábilis domének
CN115925946A (zh)	2014-05-28	2023-04-07	阿吉纳斯公司	抗gitr抗体和其使用方法
KR102485855B1 (ko)	2014-06-06	2023-01-09	2세븐티 바이오, 인코포레이티드	개선된 t 세포 조성물
NL2013007B1 (en)	2014-06-16	2016-07-05	Ablynx Nv	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en)	2014-10-21	2016-10-05	Ablynx Nv	KV1.3 Binding immunoglobulins.
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
EP3160991A2 (de)	2014-06-25	2017-05-03	Novartis AG	Zusammensetzungen und verfahren für proteine mit langer wirkung
US11542488B2 (en)	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
EP3722316A1 (de)	2014-07-21	2020-10-14	Novartis AG	Behandlung von krebs unter verwendung eines chimären cd33-antigenrezeptors
EP3193915A1 (de)	2014-07-21	2017-07-26	Novartis AG	Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
KR102612313B1 (ko)	2014-07-21	2023-12-12	노파르티스 아게	인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
EP3194976B1 (de)	2014-07-22	2020-04-01	Vib Vzw	Verfahren zur auswahl von agenten, die proteinkomplexe stabilisieren
MX2017001079A (es)	2014-07-24	2017-09-12	Bluebird Bio Inc	Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
CA2954359C (en)	2014-07-29	2018-09-25	Vrije Universiteit Brussel	Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
US20180036442A1 (en)	2014-07-29	2018-02-08	Vrije Universiteit Brussel	Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
US20170209492A1 (en)	2014-07-31	2017-07-27	Novartis Ag	Subset-optimized chimeric antigen receptor-containing t-cells
AP2017009721A0 (en)	2014-08-07	2017-01-31	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
AU2015301460B2 (en)	2014-08-14	2021-04-08	Novartis Ag	Treatment of cancer using GFR alpha-4 chimeric antigen receptor
PL3183268T3 (pl)	2014-08-19	2020-09-07	Novartis Ag	Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CR20170060A (es)	2014-08-19	2017-04-18	Merck Sharp & Dohme	Anticuerpos anti tigit
WO2016040892A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies
CN107580628B (zh)	2014-09-17	2022-01-07	诺华股份有限公司	用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
WO2016054555A2 (en)	2014-10-03	2016-04-07	Novartis Ag	Combination therapies
KR20230042391A (ko)	2014-10-03	2023-03-28	나노틱스 엘엘씨	가용성 생물분자의 생물학적 활성을 억제하기 위한 조성물 및 방법
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702688UA (en)	2014-10-10	2017-04-27	Ablynx Nv	Methods of treating rsv infections
HUE044199T2 (hu)	2014-10-10	2019-10-28	Ablynx Nv	Inhalációs készülék légúti betegségek aeroszolos terápiájában való alkalmazásra
TWI716362B (zh)	2014-10-14	2021-01-21	瑞士商諾華公司	針對ｐｄ－ｌ１之抗體分子及其用途
WO2016061632A1 (en)	2014-10-23	2016-04-28	La Trobe University	Fn14-binding proteins and uses thereof
BR112017009330A2 (pt)	2014-11-05	2017-12-19	Agrosavfe N V	planta transgênica que compreende um polinucleotídeo que codifica um domínio variável de anticorpo de cadeia pesada
US20180334490A1 (en)	2014-12-03	2018-11-22	Qilong H. Wu	Methods for b cell preconditioning in car therapy
US11001625B2 (en)	2014-12-10	2021-05-11	Tufts University	VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
AU2015360282B2 (en)	2014-12-11	2021-04-01	Pierre Fabre Medicament	Anti-C10orf54 antibodies and uses thereof
ES2750725T3 (es)	2014-12-12	2020-03-26	Bluebird Bio Inc	Receptores de antígeno quiméricos BCMA
US20160168237A1 (en)	2014-12-12	2016-06-16	Alexion Pharmaceuticals, Inc.	Method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2016094962A1 (en)	2014-12-19	2016-06-23	Monash University	Il-21 antibodies
AU2015366284B2 (en)	2014-12-19	2021-07-22	Ablynx N.V.	Cysteine linked nanobody dimers
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
US20170340733A1 (en)	2014-12-19	2017-11-30	Novartis Ag	Combination therapies
EP3237450B1 (de)	2014-12-22	2021-03-03	The Rockefeller University	Anti-mertk-antikörper und verwendungen davon
WO2016109410A2 (en)	2014-12-29	2016-07-07	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
CN107530421B (zh)	2014-12-30	2021-07-20	细胞基因公司	抗cd47抗体及其用途
DK3240801T3 (da)	2014-12-31	2021-02-08	Checkmate Pharmaceuticals Inc	Kombinationstumorimmunterapi
JP2018504400A (ja)	2015-01-08	2018-02-15	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
GB201501004D0 (en)	2015-01-21	2015-03-04	Cancer Rec Tech Ltd	Inhibitors
US11161907B2 (en)	2015-02-02	2021-11-02	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
CN107531780B (zh)	2015-02-03	2021-11-02	国家健康与医学研究院	抗-Rho GTPase的构象单域抗体及其用途
ES2791950T3 (es)	2015-02-03	2020-11-06	Ventana Med Syst Inc	Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
WO2016128549A1 (en)	2015-02-13	2016-08-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
WO2016138160A1 (en)	2015-02-24	2016-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016135041A1 (en)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3061826A1 (de)	2015-02-27	2016-08-31	Novartis AG	Flavivirus-replikons
EP4137157A1 (de)	2015-03-03	2023-02-22	Kymab Limited	Antikörper, verwendungen und verfahren
IL296062A (en)	2015-03-17	2022-10-01	Memorial Sloan Kettering Cancer Center	Antibodies against muc16 and their uses
MA41795A (fr)	2015-03-18	2018-01-23	Sarepta Therapeutics Inc	Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3271403A1 (de)	2015-03-19	2018-01-24	Regeneron Pharmaceuticals, Inc.	Nichtmenschliche tiere zur selektion von leichtkettigen variablen regionen zur antigenbindung
WO2016151557A1 (en)	2015-03-25	2016-09-29	Alexion Pharmaceuticals, Inc.	A method for measuring the protease activity of c5 convertase of the alternative complement pathway
EP3274724A1 (de)	2015-03-25	2018-01-31	Alexion Pharmaceuticals, Inc.	Verfahren zur messung der proteaseaktivität von faktor d des alternativen komplementweges
DK4089113T3 (da)	2015-03-31	2024-02-05	Sorriso Pharmaceuticals Inc	Polypeptider
BR112017020915A2 (pt)	2015-04-02	2018-07-10	Intervet Int Bv	?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune?
EP3277316A1 (de)	2015-04-02	2018-02-07	Ablynx N.V.	Bispezifische cxcr4-cd-4-polypeptide mit starker anti-hiv-wirkung
WO2016164580A1 (en)	2015-04-07	2016-10-13	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
US10851176B2 (en)	2015-04-13	2020-12-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
US9778265B2 (en)	2015-04-16	2017-10-03	The United States Of America, As Represented By The Secretary Of The Navy	Charged peptide appendage to facilitate oriented protein covalent immobilization
WO2016168601A1 (en)	2015-04-17	2016-10-20	Khalid Shah	Agents, systems and methods for treating cancer
EP3283619B1 (de)	2015-04-17	2023-04-05	Novartis AG	Verfahren zur verbesserung der wirksamkeit und expansion chimärer antigen-rezeptor-exprimierender zellen
EP3286211A1 (de)	2015-04-23	2018-02-28	Novartis AG	Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
KR20180015650A (ko)	2015-05-07	2018-02-13	아게누스 인코포레이티드	항-ox40 항체 및 이의 사용 방법
WO2016183183A1 (en)	2015-05-11	2016-11-17	The Johns Hopkins University	Autoimmune antibodies for use in inhibiting cancer cell growth
RS65904B1 (sr)	2015-05-13	2024-09-30	Ablynx Nv	Polipeptidi koji regrutuju t ćelije na osnovu reaktivnosti cd3
LT3294768T (lt)	2015-05-13	2019-11-11	Ablynx Nv	T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
IL293719B2 (en)	2015-05-21	2023-07-01	Harpoon Therapeutics Inc	Trispecific binding proteins and methods of use
WO2016191659A1 (en)	2015-05-28	2016-12-01	Bio-Rad Laboratories, Inc.	Affinity ligands and methods relating thereto
SI3303394T1 (sl)	2015-05-29	2020-10-30	Agenus Inc.	Protitelesa proti-CTLA-4 in postopki njihove uporabe
CN107614526A (zh)	2015-06-05	2018-01-19	诺华股份有限公司	靶向骨形成蛋白9(bmp9)的抗体及其方法
WO2016197367A1 (en)	2015-06-11	2016-12-15	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pd-l1 antibodies
WO2016207313A1 (en)	2015-06-24	2016-12-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and kits for detecting protein-protein interactions
JOP20200312A1 (ar)	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
AU2016294858B2 (en)	2015-07-17	2022-08-11	Vrije Universiteit Brussel	Radiolabelled antibody fragments for use in treating cancer
US10829735B2 (en)	2015-07-21	2020-11-10	The Trustees Of The University Of Pennsylvania	Methods for improving the efficacy and expansion of immune cells
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
PL3317301T3 (pl)	2015-07-29	2021-11-15	Novartis Ag	Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
CN114272371A (zh)	2015-07-29	2022-04-05	诺华股份有限公司	包含抗pd-1抗体分子的联合疗法
EP3328399B1 (de)	2015-07-31	2023-12-27	Regents of the University of Minnesota	Modifizierte zellen und therapieverfahren
US20190008983A1 (en)	2015-07-31	2019-01-10	James R. Prudent	Extracellular drug conjugates targeting cd20
AU2016303545B2 (en)	2015-08-03	2019-09-12	Novartis Ag	Methods of treating FGF21-associated disorders
WO2017020291A1 (en)	2015-08-06	2017-02-09	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pd-l1 antibodies
EP3331904B1 (de)	2015-08-07	2020-12-23	Merck Patent GmbH	Transglutamin-tag zur effizienten ortsspezifischen biokonjugation
PE20181018A1 (es)	2015-08-11	2018-06-26	Wuxi Biologics Cayman Inc	Anticuerpos anti-pd-1 novedosos
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108136014A (zh)	2015-08-31	2018-06-08	蓝鸟生物公司	抗唾液酸tn嵌合抗原受体
SG10201913276WA (en)	2015-09-01	2020-02-27	Agenus Inc	Anti-pd-1 antibodies and methods of use thereof
WO2017040930A2 (en)	2015-09-03	2017-03-09	The Trustees Of The University Of Pennsylvania	Biomarkers predictive of cytokine release syndrome
WO2017042701A1 (en)	2015-09-09	2017-03-16	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
KR20180042433A (ko)	2015-09-09	2018-04-25	노파르티스 아게	흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
UA126278C2 (uk)	2015-09-21	2022-09-14	Аптево Рісьорч Енд Девелопмент Ллс	Поліпептиди, які зв'язують cd3
WO2017062649A1 (en)	2015-10-07	2017-04-13	Alexion Pharmaceuticals, Inc.	A method for treating age-related macular degeneration in a patient
WO2017062835A2 (en)	2015-10-09	2017-04-13	Sarepta Therapeutics, Inc.	Compositions and methods for treating duchenne muscular dystrophy and related disorders
CN105238759B (zh) *	2015-10-14	2019-05-24	吉日木图	抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
US11168131B2 (en)	2015-11-10	2021-11-09	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
NO2768984T3 (de)	2015-11-12	2018-06-09
US20180327499A1 (en)	2015-11-13	2018-11-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti- nkg2d single domain antibodies and uses thereof
SG10201911035QA (en)	2015-11-18	2020-01-30	Merck Sharp & Dohme	Pd1 and/or lag3 binders
CN108473565B (zh)	2015-11-18	2022-05-27	默沙东公司	Ctla4结合剂
LT3380522T (lt)	2015-11-25	2024-02-26	Visterra, Inc.	Antikūnai prieš april molekules ir jų panaudojimas
KR20180080337A (ko)	2015-11-27	2018-07-11	아블린쓰 엔.브이.	Ｃｄ40ｌ을 억제하는 폴리펩티드
EP3797790A1 (de)	2015-12-04	2021-03-31	Boehringer Ingelheim International GmbH	Biparatopische polypeptidantagonisierende wnt-signalisierung in tumorzellen
US11479755B2 (en)	2015-12-07	2022-10-25	2Seventy Bio, Inc.	T cell compositions
US10829562B2 (en)	2015-12-10	2020-11-10	Katholieke Universiteit Leuven	Haemorrhagic disorder due to ventricular assist device
JP7000322B2 (ja)	2015-12-16	2022-02-04	メルク・シャープ・アンド・ドーム・コーポレーション	抗ｌａｇ３抗体および抗原結合性フラグメント
JP2019503349A (ja)	2015-12-17	2019-02-07	ノバルティスアーゲー	Ｐｄ−１に対する抗体分子およびその使用
JP2019502695A (ja)	2015-12-17	2019-01-31	ノバルティスアーゲー	ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
US11091556B2 (en)	2015-12-18	2021-08-17	Intervet Inc.	Caninized human antibodies to human IL-4R alpha
CA3008102A1 (en)	2015-12-18	2017-06-22	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
MA44140A (fr)	2015-12-22	2021-05-19	Dana Farber Cancer Inst Inc	Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
CN109153975A (zh)	2015-12-28	2019-01-04	诺华股份有限公司	制备嵌合抗原受体表达细胞的方法
EP3998281A1 (de)	2016-02-05	2022-05-18	Orionis Biosciences BV	Cd8-bindemittel
WO2017141208A1 (en)	2016-02-17	2017-08-24	Novartis Ag	Tgfbeta 2 antibodies
AU2017225733A1 (en)	2016-03-04	2018-09-27	Novartis Ag	Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
EP4276114A3 (de)	2016-03-07	2024-02-21	Vib Vzw	Einzeldomänenantikörper gegen cd20
JP7034489B2 (ja)	2016-03-15	2022-03-14	アイタブメッド（エイチケイ）リミテッド	多重特異性Ｆａｂ融合タンパクおよびその使用
WO2017158396A1 (en)	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
CN109153728A (zh)	2016-03-21	2019-01-04	埃尔斯塔治疗公司	多特异性和多功能分子及其用途
WO2017162604A1 (en)	2016-03-21	2017-09-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosis and treatment of solar lentigo
KR20180127971A (ko)	2016-03-23	2018-11-30	맵스페이스 바이오사이언시즈 (쑤저우) 컴퍼니 리미티드	신규 항-pd-l1 항체
EP3433275A1 (de)	2016-03-24	2019-01-30	Millennium Pharmaceuticals, Inc.	Verfahren zur behandlung gastrointestinaler immunbedingter negativer ereignisse bei immunonkologischen behandlungen
WO2017165742A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
JP7155009B2 (ja)	2016-03-25	2022-10-18	ビステラ，インコーポレイテッド	デングウイルスに対する抗体分子の製剤
WO2017176762A1 (en)	2016-04-06	2017-10-12	Nanotics, Llc	Particles comprising subparticles or nucleic acid scaffolds
EP3442993B1 (de)	2016-04-13	2021-01-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und kits zum schnellen nachweis des escherichia-coli-o25b-st131-klons
CA3020993A1 (en)	2016-04-14	2017-10-19	Bluebird Bio, Inc.	Salvage chimeric antigen receptor systems
US20170298119A1 (en)	2016-04-15	2017-10-19	Visterra, Inc.	Antibody molecules to zika virus and uses thereof
PT3443096T (pt)	2016-04-15	2023-05-30	Novartis Ag	Composições e métodos para expressão seletiva de recetores de antigénios quiméricos
US11230591B2 (en)	2016-04-20	2022-01-25	Merck Sharp & Dohme Corp.	CMV neutralizing antigen binding proteins
WO2017182605A1 (en)	2016-04-22	2017-10-26	Université Libre de Bruxelles	A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182603A1 (en)	2016-04-22	2017-10-26	Université Libre de Bruxelles	A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017189724A1 (en)	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
CN109311968A (zh)	2016-05-02	2019-02-05	埃博灵克斯股份有限公司	治疗rsv感染
CN109415432B (zh)	2016-05-02	2022-07-08	普罗塞纳生物科学有限公司	Tau免疫疗法
CN109563141A (zh)	2016-05-13	2019-04-02	奥里尼斯生物科学公司	对非细胞结构的治疗性靶向
SI3458478T1 (sl)	2016-05-18	2021-04-30	Boehringer Ingelheim International Gmbh	Anti-PD1 in anti-LAG3 protitelesa za zdravljenje raka
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
WO2017201488A1 (en)	2016-05-20	2017-11-23	Harpoon Therapeutics, Inc.	Single domain serum albumin binding protein
CN116987189A (zh)	2016-05-20	2023-11-03	哈普恩治疗公司	单链可变片段cd3结合蛋白质
WO2017202962A1 (en)	2016-05-24	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
CN118359722A (zh)	2016-05-27	2024-07-19	艾吉纳斯公司	抗tim-3抗体及其使用方法
WO2017213695A1 (en)	2016-06-07	2017-12-14	The Brigham And Women's Hospital, Inc.	Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
WO2017216724A1 (en)	2016-06-15	2017-12-21	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
WO2017223419A1 (en)	2016-06-24	2017-12-28	Ig Biosciences Corporation	Prebiotic neutraceutical compositions and methods of treatment using the same
WO2018007442A1 (en)	2016-07-06	2018-01-11	Ablynx N.V.	Treatment of il-6r related diseases
AU2017292184A1 (en)	2016-07-08	2019-02-07	Staten Biotechnology B.V.	Anti-Apoc3 antibodies and methods of use thereof
AU2017297404A1 (en)	2016-07-13	2019-01-24	Biogen Ma Inc.	Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
CA3030837A1 (en)	2016-07-15	2018-01-18	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
WO2018017964A2 (en)	2016-07-21	2018-01-25	Emory University	Ebola virus antibodies and binding agents derived therefrom
AU2017302668B9 (en)	2016-07-28	2023-06-22	Novartis Ag	Combination therapies of chimeric antigen receptors and PD-1 inhibitors
NL2017267B1 (en)	2016-07-29	2018-02-01	Aduro Biotech Holdings Europe B V	Anti-pd-1 antibodies
CN110267677A (zh)	2016-08-01	2019-09-20	诺华股份有限公司	使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
NL2017270B1 (en)	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
KR20190038607A (ko)	2016-08-02	2019-04-08	비스테라, 인크.	조작된 폴리펩티드 및 그의 용도
BR112019002127A2 (pt)	2016-08-03	2019-09-17	Nextcure Inc	proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
WO2018029182A1 (en)	2016-08-08	2018-02-15	Ablynx N.V.	Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3512880A1 (de)	2016-09-15	2019-07-24	Ablynx NV	Gegen makrophagenmigrationshemmenden faktor gerichte variable immunglobulin-einzeldomänen
JP2020502991A (ja)	2016-09-20	2020-01-30	ウーシーバイオロジクスアイルランドリミテッド	新規抗ｐｃｓｋ９抗体
RU2759334C2 (ru)	2016-09-21	2021-11-12	Нексткьюр, Инк.	Антитела против siglec-15 и способы их применения
EP4360714A3 (de)	2016-09-21	2024-07-24	Nextcure, Inc.	Antikörper für siglec-15 und verfahren zur verwendung davon
CA3034105A1 (en)	2016-09-23	2018-03-29	Csl Limited	Coagulation factor binding proteins and uses thereof
JP7274413B2 (ja)	2016-09-23	2023-05-16	マレンゴ・セラピューティクス，インコーポレーテッド	ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
EP3519438A1 (de)	2016-09-30	2019-08-07	VHsquared Limited	Zusammensetzungen
AU2017341047B2 (en)	2016-10-07	2024-10-10	Novartis Ag	Chimeric antigen receptors for the treatment of cancer
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
MX2019003683A (es)	2016-10-11	2019-08-22	Agenus Inc	Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
WO2018071624A1 (en)	2016-10-12	2018-04-19	Alexion Pharmaceuticals, Inc.	Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
EP3529359B1 (de)	2016-10-18	2023-12-13	Regents of the University of Minnesota	Tumorinfiltrierende lymphozyten zur verwendung in der therapie
JP7096240B2 (ja)	2016-10-19	2022-07-05	アレクシオンファーマシューティカルズ，インコーポレイテッド	試料中の非結合ｃ５の定量化方法
EP3529619B1 (de)	2016-10-19	2021-06-30	Alexion Pharmaceuticals, Inc.	Verfahren zur quantifizierung von ungebundenem c5a in einer probe
US11365257B2 (en)	2016-10-21	2022-06-21	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)
WO2018081400A1 (en)	2016-10-27	2018-05-03	Alexion Pharmaceuticals Inc.	Assay for c5b-9 deposition in complement-associated disorders
AU2017348365A1 (en)	2016-10-28	2019-05-23	Astute Medical, Inc.	Use of antibodies to TIMP-2 for the improvement of renal function
WO2018078083A1 (en)	2016-10-28	2018-05-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method for treating multiple myeloma
EP3534947A1 (de)	2016-11-03	2019-09-11	Kymab Limited	Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
MA46723A (fr)	2016-11-04	2019-09-11	Bluebird Bio Inc	Compositions de lymphocytes t car anti-bcma
AU2017353939A1 (en)	2016-11-07	2019-06-06	Neuracle Science Co., Ltd.	Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
CN110177809B (zh)	2016-11-16	2023-11-03	埃博灵克斯股份有限公司	能够结合CD123和TCRα/β的T细胞募集多肽
CN110072885B (zh)	2016-11-17	2023-12-19	2赛文缇生物公司	TGFβ信号转换器
US11773163B2 (en)	2016-11-21	2023-10-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the prophylactic treatment of metastases
MX2019006045A (es)	2016-11-23	2019-11-11	Harpoon Therapeutics Inc	Proteinas triespecificas dirigidas a psma y metodos de uso.
AU2017363300A1 (en)	2016-11-23	2019-06-20	Harpoon Therapeutics, Inc.	Prostate specific membrane antigen binding protein
WO2018099968A1 (en)	2016-11-29	2018-06-07	Ablynx N.V.	Treatment of infection by respiratory syncytial virus (rsv)
WO2018102746A1 (en)	2016-12-02	2018-06-07	Rigel Pharmaceuticals, Inc.	Antigen binding molecules to tigit
US20180193003A1 (en)	2016-12-07	2018-07-12	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
MX2019006340A (es)	2016-12-07	2019-11-07	Agenus Inc	Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
AU2017373945A1 (en)	2016-12-07	2019-06-20	Agenus Inc.	Antibodies and methods of use thereof
CA3046023A1 (en)	2016-12-14	2018-06-21	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112223A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a tlr modulator
CA3046093A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
AU2017378398B2 (en)	2016-12-14	2023-02-02	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
WO2018112237A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554540B1 (de)	2016-12-14	2023-08-02	Biora Therapeutics, Inc.	Behandlung von erkrankungen des gastrointestinaltraktes mit einem il-12/il-23 inhibitor mit freisetzung anhand einer essbaren vorrichtung
EP4410832A2 (de)	2016-12-14	2024-08-07	Biora Therapeutics, Inc.	Behandlung einer erkrankung des magen-darm-traktes mit einem tnf-hemmer
EP3554345A1 (de)	2016-12-14	2019-10-23	Progenity, Inc.	Behandlung von erkrankungen des gastrointestinaltraktes mit einem smad7-inhibitor
TW201834710A (zh)	2016-12-14	2018-10-01	美商寶珍那提公司	以整合素抑制劑治療胃腸道疾病
WO2018112264A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3360898A1 (de)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
CA3048156A1 (en)	2016-12-23	2018-06-28	Novartis Ag	Factor xi antibodies and methods of use
MX2019007356A (es)	2016-12-23	2019-09-05	Visterra Inc	Polipeptidos de union y metodos para fabricarlos.
MA47215A (fr)	2017-01-09	2019-11-13	Bioxcel Therapeutics Inc	Procédés prédictifs et diagnostiques pour le cancer de la prostate
CN110431150A (zh)	2017-01-18	2019-11-08	威特拉公司	抗体分子-药物偶联物及其用途
CN110662421B (zh)	2017-01-19	2023-03-24	欧莫诺艾比公司	来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
EP4043485A1 (de)	2017-01-26	2022-08-17	Novartis AG	Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
WO2018141753A1 (en)	2017-01-31	2018-08-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating squamous cell carcinomas
KR102642385B1 (ko)	2017-02-06	2024-03-04	오리오니스 바이오사이언시스 엔브이	표적화된 키메라 단백질 및 이의 용도
US10899844B2 (en)	2017-02-08	2021-01-26	Novartis Ag	FGF21 mimetic antibodies and uses thereof
WO2018151820A1 (en)	2017-02-16	2018-08-23	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
KR102616335B1 (ko)	2017-02-28	2023-12-21	브이아이비 브이지더블유	경구 단백질 전달을 위한 수단 및 방법
WO2018160731A1 (en)	2017-02-28	2018-09-07	Novartis Ag	Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3589662A4 (de)	2017-02-28	2020-12-30	Harpoon Therapeutics, Inc.	Induzierbares monovalentes antigenbindendes protein
DE202018006693U1 (de)	2017-03-14	2022-03-08	Nanotag Biotechnologies Gmbh	Target-Detektion mit einem monovalenten Antikörper
EP3596126A4 (de)	2017-03-15	2021-03-03	Tsinghua University	Neuartige anti-trkb-antikörper
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
RU2019129858A (ru)	2017-03-24	2021-03-23	Новартис Аг	Методы профилактики и лечения сердечных заболеваний
KR20190133198A (ko)	2017-03-27	2019-12-02	셀진 코포레이션	면역원성의 감소를 위한 방법 및 조성물
CA3054632A1 (en)	2017-03-30	2018-10-04	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018183932A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2018183941A2 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with live biotherapeutics
US11596670B2 (en)	2017-03-30	2023-03-07	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
WO2018183934A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
CA3055769A1 (en)	2017-04-03	2018-10-11	Oncologie, Inc.	Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
WO2018185516A1 (en)	2017-04-05	2018-10-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3609921A2 (de)	2017-04-13	2020-02-19	Agenus Inc.	Anti-cd137-antikörper und verfahren zur verwendung davon
US20200088732A1 (en)	2017-04-13	2020-03-19	INSERM (Institut National de la Santé et de la Recherche Mèdicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en)	2017-04-14	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancer
CA3058290A1 (en)	2017-04-18	2018-10-25	Universite Libre De Bruxelles	Biomarkers and targets for proliferative diseases
WO2018195283A1 (en)	2017-04-19	2018-10-25	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
JP2020517605A (ja)	2017-04-19	2020-06-18	アレクシオンファーマシューティカルズ，インコーポレイテッド	腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗ｃ５抗体の有効性
CN110506056A (zh)	2017-04-21	2019-11-26	斯塔滕生物技术有限公司	抗apoc3抗体和其使用方法
US20200055948A1 (en)	2017-04-28	2020-02-20	Novartis Ag	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (de)	2017-04-28	2020-03-04	Novartis AG	Auf bcma abzielender wirkstoff und kombinationstherapie mit einem gamma-sekretase-inhibitor
US20200385472A1 (en)	2017-04-28	2020-12-10	Elstar Therapeutics, Inc.	Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
PL3618863T3 (pl)	2017-05-01	2023-11-06	Agenus Inc.	Przeciwciała anty- tigit i sposoby ich zastosowania
KR20200005635A (ko)	2017-05-11	2020-01-15	브이아이비 브이지더블유	가변 면역글로불린 도메인의 글리코실화
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
CN110913908B (zh)	2017-05-12	2022-05-27	哈普恩治疗公司	靶向msln的三特异性蛋白质及使用方法
CN110662760A (zh)	2017-05-12	2020-01-07	奥古斯塔大学研究所公司	人甲胎蛋白特异性t细胞受体及其用途
CN113896792A (zh)	2017-05-12	2022-01-07	哈普恩治疗公司	间皮素结合蛋白质
US11225514B2 (en)	2017-05-30	2022-01-18	The Regents Of The University Of California	Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)
JP7216024B2 (ja)	2017-05-31	2023-01-31	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	腫瘍細胞におけるＷｎｔシグナル伝達と拮抗するポリペプチド
WO2018222901A1 (en)	2017-05-31	2018-12-06	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CN110691790A (zh)	2017-06-02	2020-01-14	勃林格殷格翰国际有限公司	抗癌联合治疗
SG10202113337YA (en)	2017-06-02	2021-12-30	Ablynx Nv	Aggrecan binding immunoglobulins
US12129308B2 (en)	2017-06-02	2024-10-29	Merck Patent Gmbh	MMP13 binding immunoglobulins
MX2019014397A (es)	2017-06-02	2020-02-10	Merck Patent Gmbh	Polipeptidos que enlazan adamts5, mmp13 y agrecano.
CN118894939A (zh)	2017-06-02	2024-11-05	默克专利股份有限公司	结合adamts的免疫球蛋白
EP3415010A1 (de)	2017-06-13	2018-12-19	Agrosavfe Nv	Insektenkontrollierende polypeptide und verfahren
GB201709379D0 (en)	2017-06-13	2017-07-26	Univ Leuven Kath	Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
US20190062428A1 (en)	2017-06-19	2019-02-28	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
EP3642240A1 (de)	2017-06-22	2020-04-29	Novartis AG	Antikörpermoleküle gegen cd73 und verwendungen davon
CA3066774A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
MX2019015738A (es)	2017-06-27	2020-02-20	Novartis Ag	Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
WO2019000223A1 (en)	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
US11613588B2 (en)	2017-06-28	2023-03-28	The Rockefeller University	Anti-mertk agonistic antibodies and uses thereof
CA3063659A1 (en)	2017-06-28	2019-01-03	Novartis Ag	Methods for preventing and treating urinary incontinence
JP2020530307A (ja)	2017-06-30	2020-10-22	インティマ・バイオサイエンス，インコーポレーテッド	遺伝子治療のためのアデノ随伴ウイルスベクター
CN117327187A (zh)	2017-07-11	2024-01-02	亚力兄制药公司	结合补体成分c5或血清白蛋白的多肽及其融合蛋白
SG10201913147WA (en)	2017-07-11	2020-02-27	Compass Therapeutics Llc	Agonist antibodies that bind human cd137 and uses thereof
WO2019012030A1 (en)	2017-07-13	2019-01-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
KR102625929B1 (ko)	2017-07-19	2024-01-16	브이아이비 브이지더블유	혈청 알부민 결합제
EP3431496A1 (de)	2017-07-19	2019-01-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
US20200172617A1 (en)	2017-07-20	2020-06-04	Novartis Ag	Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019016784A1 (en)	2017-07-21	2019-01-24	Universidade De Coimbra	ANTI-NUCLEOLIN ANTIBODIES
WO2019020480A1 (en)	2017-07-24	2019-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
CA3069756A1 (en)	2017-07-27	2019-01-31	Alexion Pharmaceuticals, Inc.	High concentration anti-c5 antibody formulations
JP2020529605A (ja)	2017-08-01	2020-10-08	コンパスセラピューティクスリミテッドライアビリティカンパニー	濾過およびクロマトグラフィ用ポッドならびにその使用方法
WO2019036363A1 (en)	2017-08-14	2019-02-21	Progenity Inc.	TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11485781B2 (en)	2017-08-17	2022-11-01	Massachusetts Institute Of Technology	Multiple specificity binders of CXC chemokines
EP3679070A1 (de)	2017-09-07	2020-07-15	Augusta University Research Institute, Inc.	Antikörper gegen protein 1 des programmierten zelltods
US20200268837A1 (en)	2017-09-20	2020-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for modulating autophagy
EP3692069A1 (de)	2017-10-02	2020-08-12	Visterra, Inc.	Antikörpermoleküle gegen cd138 und verwendungen davon
ES2759622T3 (es)	2017-10-02	2020-05-11	Certest Biotec S L	Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
EP3694552A1 (de)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap-antikörper und verwendungen davon
BR112020007196A2 (pt)	2017-10-13	2020-12-01	Harpoon Therapeutics, Inc.	proteínas triespecíficas e métodos de uso
EP3694871A4 (de)	2017-10-13	2021-11-10	Harpoon Therapeutics, Inc.	B-zellreifungs-antigenbindende proteine
US11713356B2 (en)	2017-10-13	2023-08-01	Ose Immunotherapeutics	Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
AU2018350370B2 (en)	2017-10-18	2023-05-04	Csl Limited	Human serum albumin variants and uses thereof
JP7422070B2 (ja)	2017-10-19	2024-01-25	デバイオファームインターナショナルエス．エー．	癌の治療のための配合剤
WO2019081983A1 (en)	2017-10-25	2019-05-02	Novartis Ag	CD32B TARGETING ANTIBODIES AND METHODS OF USE
MX2020004229A (es)	2017-10-25	2020-07-22	Novartis Ag	Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
US12128101B2 (en)	2017-10-26	2024-10-29	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
WO2019089753A2 (en)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Cd137 antibodies and pd-1 antagonists and uses thereof
SG11202003980PA (en)	2017-10-31	2020-05-28	Staten Biotechnology B V	Anti-apoc3 antibodies and methods of use thereof
JP2021502063A (ja)	2017-10-31	2021-01-28	フエー・イー・ベー・フエー・ゼツト・ウエー	新規抗原結合性キメラタンパク質とその方法及び使用
US20210179709A1 (en)	2017-10-31	2021-06-17	Novartis Ag	Anti-car compositions and methods
US20190160102A1 (en)	2017-11-03	2019-05-30	Rubius Therapeutics, Inc.	Compositions and methods related to therapeutic cell systems for tumor growth inhibition
MX2020004756A (es)	2017-11-16	2020-08-20	Novartis Ag	Terapias de combinacion.
US11851497B2 (en)	2017-11-20	2023-12-26	Compass Therapeutics Llc	CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
BR112020010514A2 (pt)	2017-11-29	2020-11-24	Csl Limited	método para tratar ou prevenir lesão por isquemia-reperfusão
WO2019106126A1 (en)	2017-12-01	2019-06-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Mdm2 modulators for the diagnosis and treatment of liposarcoma
CN112236514A (zh)	2017-12-05	2021-01-15	塞利亚德股份公司	改善细胞过继转移的持久性的组合物和方法
WO2019110667A1 (en)	2017-12-05	2019-06-13	Celyad S.A.	Reducing fratricide of immune cells expressing nkg2d-based receptors
US20200377571A1 (en)	2017-12-08	2020-12-03	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
WO2019121872A1 (en)	2017-12-20	2019-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of liver cancer
WO2019129054A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	三链抗体、其制备方法及其用途
WO2019129137A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
CN115925943A (zh)	2017-12-27	2023-04-07	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
WO2019129136A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
CN109970856B (zh)	2017-12-27	2022-08-23	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
CN117050184A (zh)	2017-12-28	2023-11-14	南京传奇生物科技有限公司	针对tigit的单域抗体和其变体
CN108218990B (zh)	2017-12-29	2021-03-02	南京优迈生物科技有限公司	分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
WO2019140116A2 (en)	2018-01-10	2019-07-18	Rubius Therapeutics, Inc.	Amplifiable rnas for therapeutic cell systems
JP7366908B2 (ja)	2018-01-15	2023-10-23	ナンジンレジェンドバイオテックカンパニー，リミテッド	Ｐｄ－１に対する単一ドメイン抗体及びその変異体
US11965191B2 (en)	2018-01-18	2024-04-23	California Institute Of Technology	Programmable protein circuits in living cells
WO2019147478A2 (en)	2018-01-18	2019-08-01	California Institute Of Technology	Programmable protein circuits in living cells
EP3743447B1 (de)	2018-01-23	2024-03-27	Nextcure, Inc.	B7-h4-antikörper und verfahren zur verwendung davon
JP2021510594A (ja)	2018-01-25	2021-04-30	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	臓器の虚血再灌流傷害を予防する方法における使用のためのｉｌ−３３のアンタゴニスト
WO2019152660A1 (en)	2018-01-31	2019-08-08	Novartis Ag	Combination therapy using a chimeric antigen receptor
EP3749690A1 (de)	2018-02-05	2020-12-16	Stichting VU	Inverse agonistische anti-us28-antikörper
JP2021513361A (ja)	2018-02-05	2021-05-27	オリオニスバイオサイエンシーズ，インコーポレイテッド	線維芽細胞結合物質およびその使用
MX2020008294A (es)	2018-02-06	2020-11-18	Ablynx Nv	Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.
US11802303B2 (en)	2018-02-07	2023-10-31	Georgia Tech Research Corporation	Methods for multiplexed cell isolation using DNA gates
WO2019156566A1 (en)	2018-02-12	2019-08-15	Umc Utrecht Holding B.V.	Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019155041A1 (en)	2018-02-12	2019-08-15	Vib Vzw	Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019158512A1 (en)	2018-02-13	2019-08-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the prognosis and the treatment of glioblastoma
WO2019169229A1 (en)	2018-03-01	2019-09-06	Nextcure, Inc.	Klrg1 binding compositions and methods of use thereof
JP2021514649A (ja)	2018-03-01	2021-06-17	ブレイエ・ユニバージテイト・ブリュッセルＶｒｉｊｅＵｎｉｖｅｒｓｉｔｅｉｔＢｒｕｓｓｅｌ	ヒトｐｄ−ｌ１結合免疫グロブリン
NL2020520B1 (en)	2018-03-02	2019-09-12	Labo Bio Medical Invest B V	Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
MX2020009507A (es)	2018-03-13	2020-10-22	Smivet B V	Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
WO2019178364A2 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
JP7037218B2 (ja)	2018-03-14	2022-03-16	サーフィスオンコロジーインコーポレイテッド	Ｃｄ３９と結合する抗体及びその使用
EP3765517A1 (de)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
EP3768720A4 (de)	2018-03-20	2022-01-05	Wuxi Biologics Ireland Limited	Neuartiges anti-lag-3-antikörper-polypeptid
CN112512571A (zh)	2018-03-22	2021-03-16	表面肿瘤学公司	抗il-27抗体及其用途
CN112384527B (zh)	2018-03-23	2023-06-27	布鲁塞尔自由大学	Wnt信号传递激动剂分子
WO2019184909A1 (zh)	2018-03-27	2019-10-03	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
WO2019185723A1 (en)	2018-03-27	2019-10-03	Umc Utrecht Holding B.V.	Targeted thrombolysis for treatment of microvascular thrombosis
US20210047696A1 (en)	2018-03-28	2021-02-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
TW202003567A (zh)	2018-03-30	2020-01-16	大陸商南京傳奇生物科技有限公司	針對lag-3之單一結構域抗體及其用途
WO2019193375A1 (en)	2018-04-04	2019-10-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fzd7 inhibitors for the treatment of retinal neovascularization
EP3775218A1 (de)	2018-04-09	2021-02-17	Checkmate Pharmaceuticals	Verkapselung von oligonukleotiden in virusähnliche partikel
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019197683A1 (en)	2018-04-13	2019-10-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
WO2019207030A1 (en)	2018-04-26	2019-10-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019210153A1 (en)	2018-04-27	2019-10-31	Novartis Ag	Car t cell therapies with enhanced efficacy
US12048745B2 (en)	2018-05-01	2024-07-30	Augusta University Research Institute, Inc.	Methods for detecting and reversing immune therapy resistance
WO2019211370A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
WO2019217913A1 (en)	2018-05-10	2019-11-14	Sensei Biotherapeutics, Inc.	Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
EP3790898A4 (de)	2018-05-10	2022-03-02	Neuracle Science Co., Ltd	Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
BR112020023330A2 (pt)	2018-05-14	2021-04-20	Harpoon Therapeutics, Inc.	porção de ligação para ativação condicional de moléculas de imunoglobulina
EP3569618A1 (de)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonisierender cd73-antikörper
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
CA3099308A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226050A2 (en)	2018-05-24	2019-11-28	Wageningen Universiteit	Novel viral anti-infective reagents
TW202015726A (zh)	2018-05-30	2020-05-01	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
CR20200571A (es)	2018-06-01	2021-01-18	Novartis Ag	Moléculas de únion contra bcma y usos de las mismas
WO2019234099A1 (en)	2018-06-06	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en)	2018-06-08	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
EP3806888B1 (de)	2018-06-12	2024-01-31	Obsidian Therapeutics, Inc.	Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
KR20210020932A (ko)	2018-06-13	2021-02-24	노파르티스 아게	Bcma 키메라 항원 수용체 및 이의 용도
EP3806903B1 (de)	2018-06-14	2024-02-14	2seventy bio, Inc.	Cd79a-chimäre antigenrezeptoren
CA3101642A1 (en)	2018-06-18	2019-12-26	Anwita Biosciences, Inc.	Anti-mesothelin constructs and uses thereof
CA3104295A1 (en)	2018-06-19	2019-12-26	Atarga, Llc	Antibody molecules to complement component 5 and uses thereof
US20230009902A1 (en)	2018-06-20	2023-01-12	Progenity, Inc.	Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020001526A1 (zh)	2018-06-29	2020-01-02	苏州智核生物医药科技有限公司	Pd-l1结合多肽及其用途
US11884729B2 (en)	2018-06-29	2024-01-30	ApitBio, Inc	Anti-L1CAM antibodies and uses thereof
CN112955465A (zh)	2018-07-03	2021-06-11	马伦戈治疗公司	抗tcr抗体分子及其用途
KR20210030973A (ko)	2018-07-11	2021-03-18	액팀 테라퓨틱스, 인코퍼레이티드	조작된 면역자극성 박테리아 균주 및 이의 용도
US20210330788A1 (en)	2018-07-11	2021-10-28	Celgene Corporation	Uses of anti-bcma chimeric antigen receptors
WO2020016160A1 (en)	2018-07-16	2020-01-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to treat neurological diseases
US20210290633A1 (en)	2018-07-19	2021-09-23	INSERM (Insstitut National de la Santé et de la Recherche Médicale)	Combination for treating cancer
EP3824287A1 (de)	2018-07-20	2021-05-26	Pierre Fabre Médicament	Rezeptor für vista
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
ES2738926A1 (es)	2018-07-26	2020-01-27	Univ Zaragoza	Granulisina, metodo de obtencion y usos
WO2020028909A1 (en)	2018-08-03	2020-02-06	Brown University	Oral formulations with increased uptake
WO2020033925A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
US20210309746A1 (en)	2018-08-09	2021-10-07	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
EP3833443A1 (de)	2018-08-09	2021-06-16	Compass Therapeutics LLC	Antigenbindende mittel, die cd277 binden, und verwendungen davon
US11453893B2 (en)	2018-08-30	2022-09-27	California Institute Of Technology	RNA-based delivery systems with levels of control
WO2020047320A1 (en)	2018-08-31	2020-03-05	California Institute Of Technology	Synthetic protein circuits detecting signal transducer activity
CA3109959A1 (en)	2018-08-31	2020-03-05	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
EP3844265A2 (de)	2018-08-31	2021-07-07	Novartis AG	Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
CN112585169A (zh)	2018-09-04	2021-03-30	南京优迈生物科技有限公司	融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用
GB201814451D0 (en)	2018-09-05	2018-10-17	Valerie Nicholas Carl Kristoffer	Methods
GB2576914A (en)	2018-09-06	2020-03-11	Kymab Ltd	Antigen-binding molecules comprising unpaired variable domains produced in mammals
US20220048947A1 (en)	2018-09-11	2022-02-17	Nanotag Biotechnologies Gmbh	Epitope tags recognized by specific binders
KR20210086623A (ko)	2018-09-25	2021-07-08	하푼 테라퓨틱스, 인크.	Ddl3 결합 단백질 및 사용 방법
WO2020064702A1 (en)	2018-09-25	2020-04-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
AU2019346645A1 (en)	2018-09-27	2021-04-29	Marengo Therapeutics, Inc.	CSF1R/CCR2 multispecific antibodies
AU2019346335B2 (en)	2018-09-28	2024-07-25	Massachusetts Institute Of Technology	Collagen-localized immunomodulatory molecules and methods thereof
WO2020070062A1 (en)	2018-10-01	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
KR20210070300A (ko)	2018-10-03	2021-06-14	스태튼 바이오테크놀로지 비.브이.	사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
WO2020070288A1 (en)	2018-10-05	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and systems for controlling the agonistic properties of antibody variable domains by light
JP2022504839A (ja)	2018-10-10	2022-01-13	ティロス・セラピューティクス・インコーポレイテッド	抗ｌａｐ抗体変異体及びその使用
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
WO2020080941A1 (en)	2018-10-16	2020-04-23	Umc Utrecht Holding B.V.	Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
US20210386788A1 (en)	2018-10-24	2021-12-16	Obsidian Therapeutics, Inc.	Er tunable protein regulation
WO2020089273A1 (en)	2018-10-31	2020-05-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating t-helper type 2 mediated disease
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
US11046769B2 (en)	2018-11-13	2021-06-29	Compass Therapeutics Llc	Multispecific binding constructs against checkpoint molecules and uses thereof
US20220026445A1 (en)	2018-12-07	2022-01-27	Georgia Tech Research Corporation	Antibodies that bind to natively folded myocilin
EP3894438A1 (de)	2018-12-13	2021-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Neuer anti-tau-svqivykpv-epitop-einzeldomänantikörper
KR20210106491A (ko)	2018-12-20	2021-08-30	노파르티스 아게	약제학적 조합물
WO2020130838A2 (en)	2018-12-21	2020-06-25	Qvq Holding B.V.	Antibodies for preventing or treating candidiasis
EP3897845A1 (de)	2018-12-21	2021-10-27	OSE Immunotherapeutics	Bifunktionelles, gegen human pd-1 gerichtetes molekül
AU2019407814A1 (en)	2018-12-21	2021-07-22	Boehringer Ingelheim International Gmbh	Bifunctional anti-PD-1/IL-7 molecule
BR112021012040A2 (pt)	2018-12-21	2021-11-03	Ose Immunotherapeutics	Molécula anti-pd-1/sirpa bifuncional
WO2020141199A1 (en)	2019-01-03	2020-07-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
US11667676B2 (en)	2019-01-10	2023-06-06	California Institute Of Technology	Synthetic system for tunable thresholding of protein signals
SG11202107606VA (en)	2019-01-15	2021-08-30	Inst Nat Sante Rech Med	Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
CN113474371A (zh)	2019-01-16	2021-10-01	指南针制药有限责任公司	与人cd137结合的抗体的制剂及其用途
WO2020148349A1 (en)	2019-01-16	2020-07-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Variants of erythroferrone and their use
TWI756621B (zh)	2019-01-25	2022-03-01	大陸商信達生物製藥（蘇州）有限公司	新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
WO2020165374A1 (en)	2019-02-14	2020-08-20	Ose Immunotherapeutics	Bifunctional molecule comprising il-15ra
US10871640B2 (en)	2019-02-15	2020-12-22	Perkinelmer Cellular Technologies Germany Gmbh	Methods and systems for automated imaging of three-dimensional objects
WO2020168024A1 (en)	2019-02-15	2020-08-20	Integral Molecular, Inc.	Antibodies comprising a common light chain and uses thereof
BR112021016056A2 (pt)	2019-02-15	2021-12-14	Integral Molecular Inc	Anticorpos de claudina 6 e usos dos mesmos
WO2020169707A1 (en)	2019-02-21	2020-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Foxo1 inhibitor for use in the treatment of latent virus infection
GB2599227B (en)	2019-02-21	2024-05-01	Marengo Therapeutics Inc	Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
EP3927744A1 (de)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	Multifunktionelle moleküle, die an t-zell-verwandte krebszellen binden, und verwendungen davon
CA3131016A1 (en)	2019-02-21	2020-08-27	Andreas Loew	Multifunctional molecules that bind to calreticulin and uses thereof
SG11202109122SA (en)	2019-02-21	2021-09-29	Marengo Therapeutics Inc	Anti-tcr antibody molecules and uses thereof
EP3927747A1 (de)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	An nkp30 bindende antikörpermoleküle und verwendungen davon
US20220088075A1 (en)	2019-02-22	2022-03-24	The Trustees Of The University Of Pennsylvania	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
DK3930847T5 (da)	2019-02-26	2024-08-05	Inspirna Inc	Anti-mertk-antistoffer med høj affinitet og anvendelser deraf
EP3930757A1 (de)	2019-03-01	2022-01-05	President And Fellows Of Harvard College	Verfahren und zusammensetzungen zur proteinabgabe
WO2020185069A1 (en)	2019-03-08	2020-09-17	Linxis B.V.	Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
WO2020185632A1 (en)	2019-03-08	2020-09-17	Obsidian Therapeutics, Inc.	Human carbonic anhydrase 2 compositions and methods for tunable regulation
WO2020193740A1 (en)	2019-03-28	2020-10-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy for treating pancreatic cancer
US20220169706A1 (en)	2019-03-28	2022-06-02	Danisco Us Inc	Engineered antibodies
MX2021011830A (es)	2019-03-29	2022-01-24	Atarga Llc	Anticuerpo anti fgf23.
WO2020205409A1 (en)	2019-04-03	2020-10-08	President And Fellows Of Harvard College	Ionic liquids for drug delivery
WO2020208082A1 (en)	2019-04-09	2020-10-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating cmv related diseases
EP3953455A1 (de)	2019-04-12	2022-02-16	Novartis AG	Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
JP2022531244A (ja)	2019-04-29	2022-07-06	コンフォセラピューティクスエヌ．ブイ．	Ｇｐｃｒに結合する化合物及びリガンドをスクリーニングするためのキメラタンパク質及び方法
US20220289837A1 (en)	2019-04-30	2022-09-15	Vib Vzw	Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
WO2020231992A1 (en)	2019-05-13	2020-11-19	Regeneron Pharmaceuticals, Inc.	Improved competitive ligand binding assays
JP2022533591A (ja)	2019-05-14	2022-07-25	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	リンホトキシンアルファ遮断剤によりターゲットされた制御性ｔ細胞及びその使用
CA3140430A1 (en)	2019-05-14	2020-11-19	Harpoon Therapeutics, Inc.	Epcam binding proteins and methods of use
EP3969472A1 (de)	2019-05-16	2022-03-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur behandlung von typ-2-entzündung oder von mastzellenabhängiger krankheit
WO2020236797A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Variant cd58 domains and uses thereof
CN114173810B (zh)	2019-05-21	2024-09-06	诺华股份有限公司	针对bcma的三特异性结合分子及其用途
CA3138360A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Cd19 binding molecules and uses thereof
WO2020238730A1 (zh)	2019-05-24	2020-12-03	三优生物医药(上海)有限公司	新型cldn18.2结合分子
EP3976067A1 (de)	2019-05-28	2022-04-06	Vib Vzw	Cd8+-t-zellen ohne plexine und ihre anwendung zur krebsbehandlung
WO2020239945A1 (en)	2019-05-28	2020-12-03	Vib Vzw	Cancer treatment by targeting plexins in the immune compartment
GB2584441A (en)	2019-06-03	2020-12-09	Fenomark Diagnostics Ab	Medical uses, methods and uses
BR112021024544A2 (pt)	2019-06-04	2022-02-08	Biotheus Inc	Anticorpo monoclonal anti-ceacam5 e método de preparação do mesmo e uso do mesmo
PE20220489A1 (es)	2019-06-12	2022-04-07	Novartis Ag	Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso
US20200392241A1 (en)	2019-06-17	2020-12-17	Visterra, Inc.	Humanized antibody molecules to cd138 and uses thereof
WO2020254619A1 (en)	2019-06-20	2020-12-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti- protease nexin-1 conformational single domain antibodies and uses thereof
CN114555643A (zh)	2019-06-21	2022-05-27	索瑞索制药公司	组合物
EP3986571A1 (de)	2019-06-21	2022-04-27	Sorriso Pharmaceuticals, Inc.	Polypeptide
JP2022538083A (ja)	2019-06-21	2022-08-31	ソリッソファーマシューティカルズ，インク．	ポリペプチド
JP2022538974A (ja)	2019-06-26	2022-09-07	マサチューセッツインスチテュートオブテクノロジー	免疫調節融合タンパク質－金属水酸化物錯体およびその方法
CN114466863A (zh)	2019-07-01	2022-05-10	苏州康宁杰瑞生物科技有限公司	百日咳毒素结合蛋白
WO2021001539A1 (en)	2019-07-04	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy to detect and treat eosinophilic fasciitis
CN114174337B (zh)	2019-07-15	2024-10-25	英特维特国际股份有限公司	针对犬ctla-4的犬源化抗体
JP7483857B2 (ja)	2019-07-26	2024-05-15	ビステラ，インコーポレイテッド	インターロイキン－２作用物質およびその使用
EP4010079A1 (de)	2019-08-05	2022-06-15	Stichting VU	Identifizierung und beseitigung von hcmv-infizierten zellen
JP2022545741A (ja)	2019-08-30	2022-10-28	アジェナスインコーポレイテッド	抗ｃｄ９６抗体およびその使用方法
BR112022003998A2 (pt)	2019-09-04	2022-05-31	Genentech Inc	Agente aglutinante de grupamento de diferenciação 8, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para fabricar um agente aglutinante de grupamento de diferenciação 8, para detectar células de grupamento de diferenciação 8 positivo, para prever a capacidade de resposta, para monitorar a progressão de doença, para monitorar o progresso do tratamento, para identificar cepas microbianas intestinais e para preparar um agente aglutinante de grupamento de diferenciação 8 rotulado, e, kit
US20220340975A1 (en)	2019-09-05	2022-10-27	INSERM (Institute National de la Santé et de la Recherche Médicale)	Method of treatment and pronostic of acute myeloid leukemia
US20220348937A1 (en)	2019-09-06	2022-11-03	Obsidian Therapeutics, Inc.	Compositions and methods for dhfr tunable protein regulation
WO2021055329A1 (en)	2019-09-16	2021-03-25	Surface Oncology, Inc.	Anti-cd39 antibody compositions and methods
JP2022548881A (ja)	2019-09-18	2022-11-22	ノバルティスアーゲー	Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
CN115087671A (zh)	2019-09-25	2022-09-20	表面肿瘤学公司	抗il-27抗体及其用途
EP4034151A1 (de)	2019-09-27	2022-08-03	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verwendung von müllerschen hemmstoff-inhibitoren zur behandlung von krebs
TW202126295A (zh)	2019-09-27	2021-07-16	大陸商江蘇挪貝肽醫藥科技有限公司	一種治療心境障礙的方法
TW202128756A (zh)	2019-10-02	2021-08-01	德商百靈佳殷格翰國際股份有限公司	用於癌症治療之多重專一性結合蛋白
EP3799881A1 (de)	2019-10-04	2021-04-07	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Einzeldomänenantikörper, die spezifisch globo binden serie glycane
US20220380456A1 (en)	2019-10-21	2022-12-01	Vib Vzw	Nanodisc-specific antigen-binding chimeric proteins
CN114786679A (zh)	2019-10-21	2022-07-22	诺华股份有限公司	具有维奈托克和tim-3抑制剂的组合疗法
EP4048285A1 (de)	2019-10-21	2022-08-31	Novartis AG	Tim-3-inhibitoren und verwendungen davon
WO2021080682A1 (en)	2019-10-24	2021-04-29	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human cd161 and uses thereof
US20230002785A1 (en)	2019-10-28	2023-01-05	Georgia Tech Research Corporation	Mrna-encoded antibodies for contraception
WO2021086953A1 (en)	2019-10-28	2021-05-06	Georgia Tech Research Corporation	Compositions and methods for prophylaxis of hiv
WO2021091978A1 (en)	2019-11-05	2021-05-14	Celgene Corporation	Uses of anti-bcma chimeric antigen receptors
EP4058477A2 (de)	2019-11-11	2022-09-21	IBI-AG Innovative Bio Insecticides Ltd.	Insektenbekämpfungsnanokörper und deren verwendungen
MX2022005705A (es)	2019-11-12	2022-08-16	Actym Therapeutics Inc	Plataformas de suministro bacteriano inmunomoduladoras y su uso para el suministro de productos terapéuticos.
EP4061338A1 (de)	2019-11-22	2022-09-28	President And Fellows Of Harvard College	Ionische flüssigkeiten zur wirkstofffreisetzung
TW202134264A (zh)	2019-11-26	2021-09-16	瑞士商諾華公司	嵌合抗原受體及其用途
WO2021105384A1 (en)	2019-11-27	2021-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Targeting the nls region of nupr1 protein to treat cancer
EP4065603A1 (de)	2019-11-27	2022-10-05	Vib Vzw	Positive allosterische modulatoren des calciumempfindlichen rezeptors
WO2021105391A1 (en)	2019-11-27	2021-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination comprising nupr1 inhibitors to treat cancer
WO2021110990A1 (en)	2019-12-05	2021-06-10	Ose Immunotherapeutics	Anti-clec-1a antibodies and antigen-binding fragment thereof
CN114980923A (zh)	2019-12-06	2022-08-30	艾伯霖克斯公司	包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽
US11897950B2 (en)	2019-12-06	2024-02-13	Augusta University Research Institute, Inc.	Osteopontin monoclonal antibodies
IL293561A (en)	2019-12-06	2022-08-01	Ablynx Nv	Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
US20230040928A1 (en)	2019-12-09	2023-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to her4 and uses thereof
BR112022010223A2 (pt)	2019-12-09	2022-09-06	Ablynx Nv	Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp)
GB201918279D0 (en)	2019-12-12	2020-01-29	Vib Vzw	Glycosylated single chain immunoglobulin domains
AU2020406083A1 (en)	2019-12-17	2022-06-16	Boehringer Ingelheim International Gmbh	Bifunctional molecules comprising an IL-7 variant
EP4077372A1 (de)	2019-12-20	2022-10-26	Vib Vzw	Nanokörperaustauschchromatographie
EP4077389A1 (de)	2019-12-20	2022-10-26	Novartis AG	Kombination des anti-tim-3-antikörpers mbg453 und des anti-tgf-beta-antikörpers nis793 mit oder ohne decitabin oder dem anti-pd-1-antikörper spartalizumab zur behandlung von myelofibrose und des myelodysplastischen syndroms
US11725048B2 (en)	2019-12-20	2023-08-15	Hudson Institute of Medical Research	CXCL10 binding proteins and compositions thereof
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
TWI845803B (zh)	2020-01-06	2024-06-21	美商法西尼克斯股份有限公司	抗ｃｃｒ８抗體及其用途
WO2021140205A1 (en)	2020-01-10	2021-07-15	Confo Therapeutics N.V.	Methods for generating antibodies and antibody fragments and libraries comprising same
TW202140553A (zh)	2020-01-13	2021-11-01	美商威特拉公司	C5ar1抗體分子及其用途
CN114929285A (zh)	2020-01-17	2022-08-19	根特大学	用于输送黏膜疫苗的免疫球蛋白单域抗体
JP2023510393A (ja)	2020-01-17	2023-03-13	ノバルティスアーゲー	骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
WO2021156490A2 (en)	2020-02-06	2021-08-12	Vib Vzw	Corona virus binders
US20230111593A1 (en)	2020-02-14	2023-04-13	Novartis Ag	Method of predicting response to chimeric antigen receptor therapy
EP4106806A4 (de)	2020-02-21	2024-07-24	Harpoon Therapeutics Inc	Flt3-bindende proteine und verfahren zur verwendung
KR20230012465A (ko)	2020-02-24	2023-01-26	이매틱스 유에스 인코포레이티드	암 및 관련 악성 종양을 치료하기 위해 t 세포를 확장하는 방법
JP2023514654A (ja)	2020-02-25	2023-04-06	ブイアイビーブイゼットダブリュ	ロイシンリッチリピートキナーゼ２のアロステリック調節因子
WO2021173674A1 (en)	2020-02-26	2021-09-02	A2 Biotherapeutics, Inc.	Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
EP4110377A2 (de)	2020-02-27	2023-01-04	Novartis AG	Verfahren zur herstellung von chimären antigenrezeptor exprimierenden zellen
CN115175695A (zh)	2020-02-27	2022-10-11	诺华股份有限公司	制备表达嵌合抗原受体的细胞的方法
CA3173527A1 (en)	2020-03-10	2021-09-16	Massachusetts Institute Of Technology	Methods for generating engineered memory-like nk cells and compositions thereof
KR20220167276A (ko)	2020-03-10	2022-12-20	매사추세츠 인스티튜트 오브 테크놀로지	NPM1c-양성 암의 면역치료를 위한 조성물 및 방법
DE102020111571A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP2023516936A (ja)	2020-03-13	2023-04-21	江蘇恒瑞医薬股▲ふん▼有限公司	Ｐｖｒｉｇ結合タンパク質及びその医薬用途
IL296330A (en)	2020-03-20	2022-11-01	Glaxosmithkline Ip Dev Ltd	A method for the detection of polysorbates
US11365239B2 (en)	2020-03-20	2022-06-21	Tsb Therapeutics (Beijing) Co., Ltd.	Anti-SARS-COV-2 antibodies and uses thereof
CN116249549A (zh)	2020-03-27	2023-06-09	诺华股份有限公司	用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
CA3175873A1 (en)	2020-03-30	2021-10-07	Ablynx Nv	Method for the production and purification of multivalent immunoglobulin single variable domains
CN113461817A (zh)	2020-03-31	2021-10-01	苏州泽璟生物制药股份有限公司	一种抗人cd47抗体及其抗原结合片段、制备方法和应用
US20230110053A1 (en)	2020-03-31	2023-04-13	Biotalys NV	Anti-fungal polypeptides
CA3178465A1 (en)	2020-04-03	2021-10-07	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
EP4132971A1 (de)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Affinitätsgereifte anti-lap-antikörper und verwendungen davon
BR112022020753A2 (pt)	2020-04-15	2022-12-20	Voyager Therapeutics Inc	Compostos de ligação a tau
JP2023522208A (ja)	2020-04-16	2023-05-29	アシスタンスピュブリック－オピトドパリ	ウイルスによって引き起こされる補体媒介性障害を処置する方法
US20230279115A1 (en)	2020-04-22	2023-09-07	Mabwell (shanghai) Bioscience Co., Ltd.	Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
KR20230028242A (ko)	2020-04-24	2023-02-28	마렝고 테라퓨틱스, 인크.	T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
AU2021267953A1 (en)	2020-05-04	2022-11-17	Immunorizon Ltd.	Precursor tri-specific antibody constructs and methods of use thereof
KR20230008751A (ko)	2020-05-12	2023-01-16	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
WO2021229104A1 (en)	2020-05-15	2021-11-18	Université de Liège	Anti-cd38 single-domain antibodies in disease monitoring and treatment
MX2022014538A (es)	2020-05-19	2022-12-15	Boehringer Ingelheim Int	Moleculas de union para el tratamiento de cancer.
WO2021233962A1 (en)	2020-05-19	2021-11-25	Institut Curie	Methods for the diagnosis and treatment of cytokine release syndrome
EP3916088A1 (de)	2020-05-28	2021-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusionsproteine, die die sars-cov-2-3-clpro-katalytische domäne enthalten, und ihre verwendung zum screening von anti-sars-cov-2-mitteln
US20230173095A1 (en)	2020-05-29	2023-06-08	President And Fellows Of Harvard College	Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
CN111647077B (zh)	2020-06-02	2021-02-09	深圳市因诺赛生物科技有限公司	新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
IL298111A (en)	2020-06-02	2023-01-01	Arcus Biosciences Inc	Antibodies to tigit
US20230332104A1 (en)	2020-06-11	2023-10-19	Novartis Ag	Zbtb32 inhibitors and uses thereof
TW202214844A (zh)	2020-06-17	2022-04-16	美商健生生物科技公司	用於製造多能幹細胞之材料及方法
US20230218608A1 (en)	2020-06-18	2023-07-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy for treating pancreatic cancer
WO2021262999A1 (en)	2020-06-24	2021-12-30	Visterra, Inc.	Antibody molecules to april and uses thereof
AU2021299932A1 (en)	2020-06-29	2023-02-02	Assistance Publique-Hôpitaux De Paris (Aphp)	Anti-protein S single-domain antibodies and polypeptides comprising thereof
US12077576B2 (en)	2020-07-02	2024-09-03	Trustees Of Tufts College	VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
WO2022003156A1 (en)	2020-07-02	2022-01-06	Oncurious Nv	Ccr8 non-blocking binders
KR20230035079A (ko)	2020-07-03	2023-03-10	수조우 알파맵 씨오., 엘티디.	응고인자 xi(fxi) 결합 단백질
CR20230009A (es)	2020-07-16	2023-01-25	Novartis Ag	Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
JP2023535708A (ja)	2020-07-21	2023-08-21	スーチョウスマートヌクライドバイオファーマシューティカルカンパニーリミテッド	Ｃｄ８結合ポリペプチドおよびその使用
JP2023535024A (ja)	2020-07-23	2023-08-15	オタープロシーナリミテッド	抗ａベータ抗体
WO2022026592A2 (en)	2020-07-28	2022-02-03	Celltas Bio, Inc.	Antibody molecules to coronavirus and uses thereof
US20230265478A1 (en)	2020-07-31	2023-08-24	Biotalys NV	Methods of increasing recombinant protein yields
CA3191433A1 (en)	2020-08-12	2022-02-17	Actym Therapeutics, Inc.	Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
WO2022040631A1 (en)	2020-08-21	2022-02-24	Immatics US, Inc.	Methods for isolating cd8+ selected t cells
AU2021331075A1 (en)	2020-08-26	2023-04-06	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
WO2022047046A1 (en)	2020-08-26	2022-03-03	Marengo Therapeutics, Inc.	Methods of detecting trbc1 or trbc2
CN116917316A (zh)	2020-08-26	2023-10-20	马伦戈治疗公司	与NKp30结合的抗体分子及其用途
EP4204020A1 (de)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Verfahren zur behandlung von psma-exprimierenden krebsarten
EP4204021A1 (de)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Verfahren zur behandlung von psma-exprimierenden krebsarten
EP4211164A1 (de)	2020-09-14	2023-07-19	Vor Biopharma Inc.	Einzeldomänenantikörper gegen cd33
JP2023541934A (ja)	2020-09-16	2023-10-04	リンクシスベスローテンフェンノートシャップ	内在化結合分子
WO2022060806A1 (en)	2020-09-16	2022-03-24	Obsidian Therapeutics, Inc.	Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2022063947A1 (en)	2020-09-24	2022-03-31	Vib Vzw	Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en)	2020-09-24	2022-03-31	Vib Vzw	Biomarker for anti-tumor therapy
MX2023003522A (es)	2020-09-25	2023-04-19	Ablynx Nv	Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
US20230416346A1 (en)	2020-10-21	2023-12-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	C-terminal sparc fragments for treating cancer
US12110335B2 (en)	2020-10-21	2024-10-08	Boehringer Ingelheim International Gmbh	Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases
US20230398149A1 (en)	2020-11-04	2023-12-14	Celgene Corporation	Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
CA3199095A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Cd19 binding molecules and uses thereof
JP2023547506A (ja)	2020-11-06	2023-11-10	ノバルティスアーゲー	Ｂ細胞悪性腫瘍を治療するための抗ｃｄ１９剤及びｂ細胞標的化剤の組み合わせ療法
CN112480248B (zh)	2020-11-24	2023-05-05	三优生物医药(上海)有限公司	与cld18a2特异性结合的分子
WO2022117572A2 (en)	2020-12-02	2022-06-09	Oncurious Nv	An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en)	2020-12-02	2022-06-09	Oncurious Nv	A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CA3203977A1 (en)	2020-12-04	2022-06-09	Visterra, Inc.	Methods of using interleukin-2 agents
US20220218614A1 (en)	2020-12-04	2022-07-14	Tidal Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
JP2023552773A (ja)	2020-12-04	2023-12-19	セルジーンコーポレーション	炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体（ｃａｒ）ｔ細胞療法の使用
US20240052042A1 (en)	2020-12-14	2024-02-15	Novartis Ag	Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
AU2021402065A1 (en)	2020-12-17	2023-06-29	Boehringer Ingelheim International Gmbh	Bifunctional anti-pd1/il-7 molecules
KR20230123497A (ko)	2020-12-18	2023-08-23	아블린쓰 엔.브이.	IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
MX2023007308A (es)	2020-12-18	2023-07-04	Ablynx Nv	Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t.
TW202241948A (zh)	2020-12-18	2022-11-01	比利時商艾伯霖克斯公司	基於TCR α/β反應性的T細胞募集多肽
GB202020502D0 (en)	2020-12-23	2021-02-03	Vib Vzw	Antibody composistion for treatment of corona virus infection
US20240052045A1 (en)	2020-12-24	2024-02-15	Vib Vzw	Murine cross-reactive human ccr8 binders
CA3206304A1 (en)	2020-12-24	2022-06-30	Vib Vzw	Human ccr8 binders
US20240052044A1 (en)	2020-12-24	2024-02-15	Vib Vzw	Non-blocking human ccr8 binders
AU2022211021A1 (en)	2021-01-20	2023-08-03	Visterra, Inc.	Interleukin-2 mutants and uses thereof
GB2603166A (en)	2021-01-29	2022-08-03	Thelper As	Therapeutic and Diagnostic Agents and Uses Thereof
JP2024505049A (ja)	2021-01-29	2024-02-02	ノバルティスアーゲー	抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
AU2022214006A1 (en)	2021-02-01	2023-09-21	St Phi Therapeutics Co., Ltd.	Targeted protein degradation system and use thereof
CA3207548A1 (en)	2021-02-05	2022-08-11	Xavier Saelens	Sarbecovirus binders
MX2023009186A (es)	2021-02-05	2023-08-21	Salubris Biotherapeutics Inc	Proteinas de fusion de il-15 y metodos para preparacion y uso de las mismas.
CN117794566A (zh)	2021-02-05	2024-03-29	Vib研究所	沙贝病毒结合剂
US20240229154A9 (en)	2021-02-12	2024-07-11	Institut National de la Santé et de la Recherche Médicale	Method for prognosis and treating a patient suffering from cancer
US20240130999A1 (en)	2021-02-17	2024-04-25	Vib Vzw	Inhibition of SLC4A4 in the Treatment of Cancer
MX2023009716A (es)	2021-02-19	2024-01-08	Shaperon Inc	Anticuerpo de dominio individual contra ligando de muerte programada 1 (pd-l1) y uso del mismo.
US20240228670A9 (en)	2021-02-19	2024-07-11	Shaperon Inc.	Bispecific single domain antibody to pd-l1 and cd47 and use thereof
AU2022222994A1 (en)	2021-02-19	2023-09-28	Seoul National University R&Db Foundation	Single domain antibody against cd47 and use thereof
WO2022175532A1 (en)	2021-02-19	2022-08-25	Vib Vzw	Cation-independent mannose-6-phosphate receptor binders
CN117321076A (zh)	2021-02-19	2023-12-29	美国卫生及公众服务部代表	中和SARS-CoV-2的单结构域抗体
JP2024511373A (ja)	2021-03-18	2024-03-13	ノバルティスアーゲー	がんのためのバイオマーカーおよびその使用
WO2022199804A1 (en)	2021-03-24	2022-09-29	Vib Vzw	Nek6 inhibition to treat als and ftd
GB202104104D0 (en)	2021-03-24	2021-05-05	Liliumx Ltd	Platform and method
JP2024514530A (ja)	2021-04-02	2024-04-02	ザリージェンツオブザユニバーシティオブカリフォルニア	切断型ｃｄｃｐ１に対する抗体およびその使用
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022255166A1 (en)	2021-04-07	2023-09-28	Century Therapeutics, Inc.	Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
MX2023011927A (es)	2021-04-07	2023-10-23	Century Therapeutics Inc	Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
AU2022253223A1 (en)	2021-04-07	2023-09-28	Century Therapeutics, Inc.	Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
AU2022255506A1 (en)	2021-04-08	2023-11-09	Marengo Therapeutics, Inc.	Multifunctional molecules binding to tcr and uses thereof
WO2022214653A1 (en)	2021-04-09	2022-10-13	Ose Immunotherapeutics	New scaffold for bifunctional molecules with improved properties
EP4320229A1 (de)	2021-04-09	2024-02-14	Stichting Radboud Universiteit	Endlagernähe-biotylierungsenzym
EP4320156A1 (de)	2021-04-09	2024-02-14	Ose Immunotherapeutics	Gerüst für bifunctioanlmoleküle mit pd-1- oder cd28- und sirp-bindenden domänen
WO2022219080A1 (en)	2021-04-14	2022-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method to improve nk cells cytotoxicity
WO2022219076A1 (en)	2021-04-14	2022-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method to improve the anti-tumoral activity of macrophages
JP2024517413A (ja)	2021-04-16	2024-04-22	セルジーンコーポレーション	以前に幹細胞移植を受けた患者におけるｔ細胞療法
CA3219609A1 (en)	2021-05-04	2022-11-10	Regeneron Pharmaceuticals, Inc.	Multispecific fgf21 receptor agonists and their uses
JP2024516970A (ja)	2021-05-07	2024-04-18	サーフィスオンコロジー，エルエルシー	抗ｉｌ－２７抗体及びその使用
WO2022242892A1 (en)	2021-05-17	2022-11-24	Université de Liège	Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022253910A1 (en)	2021-06-02	2022-12-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	A new method to treat an inflammatory skin disease
JP2024523436A (ja)	2021-06-16	2024-06-28	上海▲シン▼湾生物科技有限公司	Ａｘｌタンパク質を標的とする抗体及びその抗原結合断片、その調製方法と使用
AR126161A1 (es)	2021-06-17	2023-09-27	Boehringer Lngelheim Int Gmbh	Moléculas de fijación triespecíficas novedosas
AU2022299282A1 (en)	2021-06-22	2024-02-01	Merck Patent Gmbh	Vhh-based nkp30 binders
US20230174651A1 (en)	2021-06-23	2023-06-08	Janssen Biotech, Inc.	Materials and methods for hinge regions in functional exogenous receptors
CA3225194A1 (en)	2021-06-23	2022-12-29	Vib Vzw	Means and methods for selection of specific binders
CN114230665B (zh)	2021-06-23	2024-03-22	苏州智核生物医药科技有限公司	CD8α结合多肽及其用途
JP2024524378A (ja)	2021-06-29	2024-07-05	山▲東▼先声生物制▲薬▼有限公司	Ｃｄ１６抗体及びその応用
EP4370160A1 (de)	2021-07-15	2024-05-22	President And Fellows Of Harvard College	Zusammensetzungen und verfahren in zusammenhang mit zellen mit anhaftenden partikeln
CA3228014A1 (en)	2021-07-30	2023-02-16	Vib Vzm	Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
CN117751143A (zh)	2021-07-30	2024-03-22	山东先声生物制药有限公司	抗pvrig/抗tigit双特异性抗体和应用
JP2024530943A (ja)	2021-08-06	2024-08-27	アンスティテュ・レジオナル・デュ・カンセール・ドゥ・モンペリエ	がんの処置のための方法
WO2023023220A1 (en)	2021-08-20	2023-02-23	Alexion Pharmaceuticals, Inc.	Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023023227A1 (en)	2021-08-20	2023-02-23	Alexion Pharmaceuticals, Inc.	Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
CA3228641A1 (en)	2021-08-24	2023-03-02	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Fap/cd40 binding molecule and medicinal use thereof
WO2023041985A2 (en)	2021-09-15	2023-03-23	New York University In Abu Dhabicorporation	Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
EP4403573A1 (de)	2021-09-15	2024-07-24	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pharmazeutische zusammensetzung mit bispezifischem anti-pvrig/tigit-antikörper
TW202328195A (zh)	2021-09-15	2023-07-16	大陸商江蘇恆瑞醫藥股份有限公司	特異性結合ｐｄ－１的蛋白及其醫藥用途
EP4401715A1 (de)	2021-09-17	2024-07-24	Institut Curie	Bet-inhibitoren zur behandlung von pab1-defizientem krebs
WO2023044483A2 (en)	2021-09-20	2023-03-23	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
EP4405680A1 (de)	2021-09-20	2024-07-31	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur verbesserung der wirksamkeit einer hdac-hemmertherapie und vorhersage der reaktion auf die behandlung mit hdac-hemmer
WO2023057601A1 (en)	2021-10-06	2023-04-13	Biotalys NV	Anti-fungal polypeptides
EP4413165A1 (de)	2021-10-06	2024-08-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur vorhersage und verbesserung der wirksamkeit einer mcl-1-inhibitortherapie
KR20240082406A (ko)	2021-10-08	2024-06-10	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	약물 전달을 위한 이온성 액체
WO2023061005A1 (zh)	2021-10-14	2023-04-20	徕特康(苏州)生物制药有限公司	新型抗体-细胞因子融合蛋白及其制备方法和用途
WO2023073099A1 (en)	2021-10-28	2023-05-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to improve phagocytosis
WO2023078906A1 (en)	2021-11-03	2023-05-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating acute myeloid leukemia
EP4177266A1 (de)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralisierende humane anti-sars-cov-2-antikörper
WO2023079137A1 (en)	2021-11-05	2023-05-11	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
WO2023086796A2 (en)	2021-11-09	2023-05-19	Actym Therapeutics, Inc.	Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
WO2023083890A1 (en)	2021-11-09	2023-05-19	Ose Immunotherapeutics	Identification of clec-1 ligand and uses thereof
EP4180518A1 (de)	2021-11-12	2023-05-17	Istituto Europeo di Oncologia S.r.l.	T-zellen und deren verwendungen
WO2023092004A1 (en)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2023089032A1 (en)	2021-11-19	2023-05-25	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
EP4437547A1 (de)	2021-11-22	2024-10-02	Ablynx N.V.	Gewinnung von sequenzinformationen für multivalente und multivalente immunglobulin-einzelvariablen-domänen
WO2023089159A1 (en)	2021-11-22	2023-05-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy targeting stroma/tumor cell crosstalk to treat a cancer
CN118632860A (zh)	2021-11-24	2024-09-10	诺华股份有限公司	腺相关病毒转导调节剂及其用途
US20230348614A1 (en)	2021-11-24	2023-11-02	Visterra, Inc.	Engineered antibody molecules to cd138 and uses thereof
TW202330596A (zh)	2021-11-29	2023-08-01	大陸商江蘇恆瑞醫藥股份有限公司	經修飾的蛋白或多肽
EP4442273A1 (de)	2021-11-30	2024-10-09	Suzhou Alphamab Co., Ltd.	Verfahren zur prävention und/oder behandlung thromboembolischer erkrankungen
TW202333772A (zh)	2021-12-01	2023-09-01	美商威特拉公司	使用介白素-2藥劑之方法
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
EP4428156A1 (de)	2021-12-03	2024-09-11	Shandong Simcere Biopharmaceutical Co., Ltd.	Anti-bcma-nanokörper und verwendung davon
IL313473A (en)	2021-12-15	2024-08-01	Interius Biotherapeutics Inc	Identical viral particles, the compositions containing them and their uses
TW202342508A (zh)	2021-12-17	2023-11-01	比利時商艾伯霖克斯公司	包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
CN118510805A (zh)	2021-12-31	2024-08-16	山东先声生物制药有限公司	一种gprc5d抗体及其应用
EP4209508A1 (de)	2022-01-11	2023-07-12	Centre national de la recherche scientifique	Nanokörpern für das deneddylierende enzym nedp1
WO2023135198A1 (en)	2022-01-12	2023-07-20	Vib Vzw	Human ntcp binders for therapeutic use and liver-specific targeted delivery
GB202201137D0 (en)	2022-01-28	2022-03-16	Thelper As	Therapeutic and diagnostic agents and uses thereof
WO2023148291A1 (en)	2022-02-02	2023-08-10	Biotalys NV	Methods for genome editing
WO2023148397A1 (en)	2022-02-07	2023-08-10	Vib Vzw	Engineered stabilizing aglycosylated fc-regions
CN118647633A (zh)	2022-02-07	2024-09-13	威斯特拉公司	抗独特型抗体分子及其用途
WO2023151894A1 (en)	2022-02-11	2023-08-17	Henkel Ag & Co. Kgaa	Process for the synthesis of alpha-methylene-gamma-butyrolactone
WO2023164487A1 (en)	2022-02-22	2023-08-31	Brown University	Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
WO2023183477A1 (en)	2022-03-23	2023-09-28	Bodhi Bio Llc	Compositions and methods for antigen-specific therapy
IL315552A (en)	2022-03-30	2024-11-01	Novartis Ag	Methods for treating disorders using anti-natriuretic peptide 1 (NPR1) antibodies
WO2023201238A1 (en)	2022-04-11	2023-10-19	Vor Biopharma Inc.	Binding agents and methods of use thereof
WO2023198848A1 (en)	2022-04-13	2023-10-19	Vib Vzw	An ltbr agonist in combination therapy against cancer
WO2023198806A1 (en)	2022-04-13	2023-10-19	Ose Immunotherapeutics	New class of molecules for selective clearance of antibody
WO2023198851A1 (en)	2022-04-14	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for controlling the tumor cell killing by light
US20240092921A1 (en)	2022-04-25	2024-03-21	Visterra, Inc.	Antibody molecules to april and uses thereof
WO2023212587A1 (en)	2022-04-28	2023-11-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
WO2023213751A1 (en)	2022-05-02	2023-11-09	Umc Utrecht Holding B.V	Single domain antibodies for the detection of plasmin-cleaved vwf
AU2023264591A1 (en)	2022-05-02	2024-11-07	Arcus Biosciences, Inc.	Anti-tigit antibodies and uses of the same
WO2023217904A1 (en)	2022-05-10	2023-11-16	Institut National de la Santé et de la Recherche Médicale	Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
WO2023220647A1 (en)	2022-05-11	2023-11-16	Regeneron Pharmaceuticals, Inc.	Multispecific binding molecule proproteins and uses thereof
WO2023220695A2 (en)	2022-05-13	2023-11-16	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
WO2023222825A1 (en)	2022-05-18	2023-11-23	Vib Vzw	Sarbecovirus spike s2 subunit binders
US20230372395A1 (en)	2022-05-19	2023-11-23	Massachusetts Institute Of Technology	Car cells targeting an inserted ligand
WO2023230128A1 (en)	2022-05-25	2023-11-30	Surface Oncology, Inc.	Use of anti-il-27 antibodies
WO2023230548A1 (en)	2022-05-25	2023-11-30	Celgene Corporation	Method for predicting response to a t cell therapy
US20240025987A1 (en)	2022-05-25	2024-01-25	Surface Oncology, Inc.	Use of anti-il-27 antibodies
WO2023232826A1 (en)	2022-05-30	2023-12-07	Ose Immunotherapeutics	Biomarkers of il7r modulator activity
WO2023240109A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240124A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
US20240002331A1 (en)	2022-06-08	2024-01-04	Tidal Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US20240109965A1 (en)	2022-06-14	2024-04-04	Ablynx N.V.	Immunoglobulin single variable domains targeting t cell receptor
WO2024003873A1 (en)	2022-06-30	2024-01-04	Intrexon Actobiotics Nv D/B/A Precigen Actobio	Single variable domain antibodies against tumor necrosis factor-alpha
EP4299125A1 (de)	2022-06-30	2024-01-03	Universite De Montpellier	Anti-mglur2-biparatopische nanokörper und deren verwendungen
EP4299124A1 (de)	2022-06-30	2024-01-03	Universite De Montpellier	Anti-mglur2-nanokörper zur verwendung als biomolekültransporter
WO2024008755A1 (en)	2022-07-04	2024-01-11	Vib Vzw	Blood-cerebrospinal fluid barrier crossing antibodies
KR20240007881A (ko)	2022-07-08	2024-01-17	노보 노르디스크 에이/에스	FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
WO2024008904A2 (en)	2022-07-08	2024-01-11	Novo Nordisk A/S	Highly potent isvd compounds capable of substituting for fviii(a)
US20240052065A1 (en)	2022-07-15	2024-02-15	Boehringer Ingelheim International Gmbh	Binding molecules for the treatment of cancer
TW202417502A (zh)	2022-07-18	2024-05-01	比利時商艾伯霖克斯公司	Cx3cr1結合化合物、方法及其用途
WO2024018426A1 (en)	2022-07-22	2024-01-25	Janssen Biotech, Inc.	Enhanced transfer of genetic instructions to effector immune cells
WO2024023271A1 (en)	2022-07-27	2024-02-01	Ablynx Nv	Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024028347A1 (en)	2022-08-01	2024-02-08	Ose Immunotherapeutics	Heterodimeric fc-clec-1 fusion molecule and uses thereof
WO2024028386A1 (en)	2022-08-02	2024-02-08	Ose Immunotherapeutics	Multifunctional molecule directed against cd28
WO2024030976A2 (en)	2022-08-03	2024-02-08	Voyager Therapeutics, Inc.	Compositions and methods for crossing the blood brain barrier
WO2024028476A1 (en)	2022-08-05	2024-02-08	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en)	2022-08-17	2024-02-22	Institut National de la Santé et de la Recherche Médicale	Syk inhibitors for use in the treatment of cancer
WO2024047110A1 (en)	2022-08-31	2024-03-07	Institut National de la Santé et de la Recherche Médicale	Method to generate more efficient car-t cells
TW202417490A (zh)	2022-08-31	2024-05-01	美商艾力克森製藥公司	用於治療鐮狀細胞病的融合多肽之劑量及投與
WO2024050524A1 (en)	2022-09-01	2024-03-07	University Of Georgia Research Foundation, Inc.	Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054436A1 (en)	2022-09-06	2024-03-14	Alexion Pharmaceuticals, Inc.	Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024055034A1 (en)	2022-09-09	2024-03-14	Yale University	Proteolysis targeting antibodies and methods of use thereof
WO2024056809A1 (en)	2022-09-15	2024-03-21	Novartis Ag	Treatment of autoimmune disorders using chimeric antigen receptor therapy
WO2024059739A1 (en)	2022-09-15	2024-03-21	Voyager Therapeutics, Inc.	Tau binding compounds
WO2024068744A1 (en)	2022-09-27	2024-04-04	Vib Vzw	Antivirals against human parainfluenza virus
WO2024069180A2 (en)	2022-09-28	2024-04-04	LiliumX Ltd.	Multivalent proteins and screening methods
TW202430561A (zh)	2022-09-30	2024-08-01	法商賽諾菲公司	抗cd28抗體
WO2024074713A1 (en)	2022-10-07	2024-04-11	Institut National de la Santé et de la Recherche Médicale	Method to generate improving car-t cells
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024096735A1 (en)	2022-10-31	2024-05-10	Stichting Amsterdam UMC	Single domain anti-cd169 antibodies
WO2024101989A1 (en)	2022-11-08	2024-05-16	Stichting Amsterdam UMC	Activation inducible antigen receptors for adoptive immunotherapy
WO2024102962A1 (en)	2022-11-10	2024-05-16	Immuvia Inc	Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
WO2024105091A1 (en)	2022-11-15	2024-05-23	Imec Vzw	Method and system for droplet manipulation
US12110344B2 (en)	2022-11-21	2024-10-08	Dianthus Therapeutics Opco, Inc.	Antibodies that bind to cis and uses thereof
TW202430574A (zh)	2022-11-30	2024-08-01	美商積分分子股份有限公司	針對密連蛋白６之抗體，包括其雙特異性格式
WO2024119074A1 (en)	2022-12-01	2024-06-06	Generation Bio Co.	Stealth lipid nanoparticle compositions for cell targeting
WO2024123963A2 (en)	2022-12-07	2024-06-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
WO2024126363A1 (en)	2022-12-12	2024-06-20	Institut National de la Santé et de la Recherche Médicale	Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
US20240200085A1 (en)	2022-12-15	2024-06-20	Aarhus Universitet	Synthetic activation of multimeric transmembrane receptors
WO2024133301A1 (en)	2022-12-19	2024-06-27	Umc Utrecht Holding B.V.	Btn2a1 binding peptide
US20240209107A1 (en)	2022-12-19	2024-06-27	Sanofi	Cd28/ox40 bispecific antibodies
US20240262923A1 (en)	2022-12-21	2024-08-08	Genzyme Corporation	Anti-pd-1×4-1bb binding proteins
WO2024133937A1 (en)	2022-12-22	2024-06-27	Biotalys NV	Methods for genome editing
WO2024133723A1 (en)	2022-12-22	2024-06-27	Institut National de la Santé et de la Recherche Médicale	Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
WO2024133935A1 (en)	2022-12-23	2024-06-27	Ablynx Nv	Protein-based conjugation carriers
WO2024145551A1 (en)	2022-12-29	2024-07-04	Biotalys NV	Agrochemical compositions
WO2024141645A1 (en)	2022-12-30	2024-07-04	Biotalys N.V.	Agglomerate
WO2024141638A1 (en)	2022-12-30	2024-07-04	Biotalys NV	Self-emulsifiable concentrate
WO2024141641A2 (en)	2022-12-30	2024-07-04	Biotalys NV	Secretion signals
WO2024151515A2 (en)	2023-01-09	2024-07-18	Odyssey Therapeutics, Inc.	Anti-tnfr2 antigen-binding proteins and uses thereof
WO2024152014A1 (en)	2023-01-13	2024-07-18	Regeneron Pharmaceuticals, Inc.	Fgfr3 binding molecules and methods of use thereof
WO2024157085A1 (en)	2023-01-26	2024-08-02	Othair Prothena Limited	Methods of treating neurological disorders with anti-abeta antibodies
WO2024156881A1 (en)	2023-01-27	2024-08-02	Vib Vzw	CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en)	2023-01-27	2024-08-02	Vib Vzw	Cd163-binding conjugates
WO2024165500A1 (en)	2023-02-06	2024-08-15	Merck Patent Gmbh	Vhh-based nkp46 binders
WO2024168061A2 (en)	2023-02-07	2024-08-15	Ayan Therapeutics Inc.	Antibody molecules binding to sars-cov-2
WO2024165710A1 (en)	2023-02-09	2024-08-15	Seni-Preps B.V.	Immunoglobulin single variable domains that inhibit urease and use thereof
US20240327538A1 (en)	2023-02-10	2024-10-03	Amunix Pharmaceuticals, Inc.	Compositions targeting prostate-specific membrane antigen and methods for making and using the same
US20240368250A1 (en)	2023-02-17	2024-11-07	Ablynx N.V.	Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en)	2023-02-24	2024-08-29	Vrije Universiteit Brussel	Anti-inflammatory pannexin 1 channel inhibitors
WO2024184812A1 (en)	2023-03-06	2024-09-12	Beigene Switzerland Gmbh	Anti-cldn6 antibodies and methods of use
WO2024184811A1 (en)	2023-03-06	2024-09-12	Beigene Switzerland Gmbh	Anti-cd3 multispecific antibodies and methods of use
WO2024184810A1 (en)	2023-03-06	2024-09-12	Beigene Switzerland Gmbh	Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184476A1 (en)	2023-03-07	2024-09-12	Institut Curie	Ung/udg inhibition in brca-associated cancer
WO2024184479A1 (en)	2023-03-08	2024-09-12	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of food allergy
WO2024189171A1 (en)	2023-03-14	2024-09-19	Aarhus Universitet	Genetically altered nfr5 receptor kinases
WO2024192065A1 (en)	2023-03-14	2024-09-19	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof
WO2024194402A1 (en)	2023-03-21	2024-09-26	Institut Curie	Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024194401A1 (en)	2023-03-21	2024-09-26	Institut Curie	Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en)	2023-03-21	2024-09-26	Institut Curie	Methods for the treatment of dedifferentiated liposarcoma
WO2024197296A1 (en)	2023-03-23	2024-09-26	Bodhi Bio Llc	Compositions and methods for antigen-specific therapy
WO2024200332A1 (en)	2023-03-24	2024-10-03	Sanofi	Asthma treatment by blocking il-13 and tslp
EP4435005A1 (de)	2023-03-24	2024-09-25	Sanofi	Asthmabehandlung durch blockierung von il-13 und tslp
WO2024200846A1 (en)	2023-03-30	2024-10-03	272BIO Limited	Gnrh-binding polypeptides and uses thereof
WO2024208816A1 (en)	2023-04-03	2024-10-10	Vib Vzw	Blood-brain barrier crossing antibodies
WO2024213782A1 (en)	2023-04-13	2024-10-17	Institut Curie	Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024224323A1 (en)	2023-04-24	2024-10-31	King Abdullah University Of Science Of Technology	Compositions, systems and methods for multiplex detection of target biomarkers in a sample
WO2024226829A2 (en)	2023-04-26	2024-10-31	Yale University	Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en) *	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
GB9016299D0 (en) *	1990-07-25	1990-09-12	Brien Caroline J O	Binding substances

1993
- 1993-08-18 AT AT05008358T patent/ATE452975T1/de active
- 1993-08-18 DK DK00127968T patent/DK1087013T3/da active
- 1993-08-18 DK DK05008358.3T patent/DK1589107T3/da active
- 1993-08-18 DE DE69330523A patent/DE69330523D1/de not_active Expired - Lifetime
- 1993-08-18 DE DE69330523T patent/DE69330523T4/de not_active Expired - Lifetime
- 1993-08-18 DE DE69334308T patent/DE69334308D1/de not_active Expired - Lifetime
- 1993-08-18 ES ES93919098T patent/ES2162823T5/es not_active Expired - Lifetime
- 1993-08-18 AT AT04077639T patent/ATE452207T1/de active
- 1993-08-18 ES ES00127968T patent/ES2322324T3/es not_active Expired - Lifetime
- 1993-08-18 AT AT93919098T patent/ATE203767T1/de active
- 1993-08-18 EP EP93919098A patent/EP0656946B2/de not_active Expired - Lifetime
- 1993-08-18 EP EP05020889A patent/EP1621554B2/de not_active Expired - Lifetime
- 1993-08-18 DK DK04077639.5T patent/DK1498427T3/da active
- 1993-08-18 PT PT04077639T patent/PT1498427E/pt unknown
- 1993-08-18 PT PT00127968T patent/PT1087013E/pt unknown
- 1993-08-18 DK DK05020889.1T patent/DK1621554T4/da active
- 1993-08-18 AT AT00127968T patent/ATE420178T1/de active
- 1993-08-18 EP EP04077639A patent/EP1498427B1/de not_active Expired - Lifetime
- 1993-08-18 EP EP05008358A patent/EP1589107B1/de not_active Expired - Lifetime
- 1993-08-18 DK DK93919098.9T patent/DK0656946T4/da active
- 1993-08-18 PT PT93919098T patent/PT656946E/pt unknown
- 1993-08-18 AU AU49497/93A patent/AU701578B2/en not_active Ceased
- 1993-08-18 WO PCT/EP1993/002214 patent/WO1994004678A1/en active IP Right Grant
- 1993-08-18 ES ES04077639T patent/ES2338321T3/es not_active Expired - Lifetime
- 1993-08-18 DE DE69334258T patent/DE69334258D1/de not_active Expired - Lifetime
- 1993-08-18 DE DE69334275T patent/DE69334275D1/de not_active Expired - Lifetime
- 1993-08-18 EP EP09174252A patent/EP2192131A1/de active Pending
- 1993-08-18 EP EP00127968A patent/EP1087013B1/de not_active Expired - Lifetime
- 1993-08-18 PT PT05020889T patent/PT1621554E/pt unknown
- 1993-08-18 PT PT05008358T patent/PT1589107E/pt unknown
- 1993-08-18 ES ES05008358T patent/ES2338791T3/es not_active Expired - Lifetime
- 1993-08-18 DE DE69334305T patent/DE69334305D1/de not_active Expired - Lifetime
- 1993-08-18 CA CA002142331A patent/CA2142331C/en not_active Expired - Lifetime
- 1993-08-18 JP JP50590394A patent/JP3444885B2/ja not_active Expired - Fee Related
- 1993-08-18 AT AT05020889T patent/ATE427968T1/de active
- 1993-08-18 ES ES05020889T patent/ES2325541T3/es not_active Expired - Lifetime
1995
- 1995-02-20 FI FI950782A patent/FI115462B/fi not_active IP Right Cessation
- 1995-06-06 US US08/471,282 patent/US5840526A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,780 patent/US5759808A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,282 patent/US5800988A/en not_active Expired - Lifetime
- 1995-06-06 US US08/468,739 patent/US6015695A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,710 patent/US5874541A/en not_active Expired - Lifetime
2001
- 2001-05-07 JP JP2001136457A patent/JP3660270B2/ja not_active Expired - Lifetime
- 2001-10-25 GR GR20010401895T patent/GR3037024T3/el unknown
2004
- 2004-12-08 FI FI20041584A patent/FI117975B/fi not_active IP Right Cessation
2005
- 2005-01-18 JP JP2005010359A patent/JP4414900B2/ja not_active Expired - Lifetime
2007
- 2007-02-28 FI FI20070170A patent/FI120404B/fi not_active IP Right Cessation
2009
- 2009-08-21 JP JP2009192382A patent/JP2009280608A/ja active Pending

Also Published As

Publication number	Publication date
DK1621554T3 (da)	2009-08-10
EP1087013A3 (de)	2001-11-28
WO1994004678A1 (en)	1994-03-03
JP3444885B2 (ja)	2003-09-08
PT1621554E (pt)	2009-07-13
CA2142331C (en)	2010-02-02
PT1589107E (pt)	2010-03-29
DE69330523T3 (de)	2010-10-28
ATE203767T1 (de)	2001-08-15
AU4949793A (en)	1994-03-15
AU701578B2 (en)	1999-02-04
US5759808A (en)	1998-06-02
ATE452207T1 (de)	2010-01-15
EP1589107B1 (de)	2009-12-23
DK1087013T3 (da)	2009-05-11
DE69330523T4 (de)	2012-08-23
DE69334305D1 (de)	2010-01-28
JPH08500487A (ja)	1996-01-23
EP1621554B2 (de)	2012-08-29
JP2009280608A (ja)	2009-12-03
EP1498427A1 (de)	2005-01-19
CA2142331A1 (en)	1994-03-03
EP0656946B1 (de)	2001-08-01
DE69330523T2 (de)	2002-03-28
FI950782A (fi)	1995-04-20
US5800988A (en)	1998-09-01
ATE427968T1 (de)	2009-04-15
JP4414900B2 (ja)	2010-02-10
EP0656946A1 (de)	1995-06-14
ES2162823T5 (es)	2010-08-09
FI115462B (fi)	2005-05-13
EP1589107A1 (de)	2005-10-26
EP1498427B1 (de)	2009-12-16
DE69330523D1 (de)	2001-09-06
DE69334308D1 (de)	2010-02-04
EP1087013A2 (de)	2001-03-28
PT1498427E (pt)	2010-03-22
JP2002053600A (ja)	2002-02-19
DK0656946T3 (da)	2001-11-05
ES2162823T3 (es)	2002-01-16
DK1589107T3 (da)	2010-04-26
PT656946E (pt)	2001-12-28
ES2325541T3 (es)	2009-09-08
EP2192131A1 (de)	2010-06-02
EP0656946B2 (de)	2010-03-31
EP1087013B1 (de)	2009-01-07
FI117975B (fi)	2007-05-15
ES2322324T3 (es)	2009-06-19
FI950782A0 (fi)	1995-02-20
FI20041584A (fi)	2004-12-08
US5874541A (en)	1999-02-23
ATE420178T1 (de)	2009-01-15
JP2005170953A (ja)	2005-06-30
DK1498427T3 (da)	2010-04-26
FI120404B (fi)	2009-10-15
PT1087013E (pt)	2009-04-15
ES2338321T3 (es)	2010-05-06
GR3037024T3 (en)	2002-01-31
DK1621554T4 (da)	2012-12-17
JP3660270B2 (ja)	2005-06-15
DE69334258D1 (de)	2009-02-26
ES2338791T3 (es)	2010-05-12
US5840526A (en)	1998-11-24
EP1621554B1 (de)	2009-04-08
US6015695A (en)	2000-01-18
EP1621554A1 (de)	2006-02-01
DK0656946T4 (da)	2010-07-26
FI20070170A (fi)	2007-02-28
DE69334275D1 (de)	2009-05-20

Publication	Publication Date	Title
ATE452207T1 (de)	2010-01-15	Immunoglobuline ohne leichte ketten
DK0975771T3 (da)	2007-10-22	Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region
DE69327229D1 (de)	2000-01-13	Multivalente einkettige Antikörper
ATE391179T1 (de)	2008-04-15	Variable fragmente von immunoglobulinen und ihre verwendung zu therapeutischen oder veterinären zwecken
FI965032A (fi)	1996-12-16	Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
DE69133326D1 (de)	2003-11-13	Verbesserte humanähnlich gemachte immunglobuline
ATE166883T1 (de)	1998-06-15	Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
ITRM920223A0 (it)	1992-03-27	Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.

Legal Events

Date	Code	Title	Description
2010-07-15	UEP	Publication of translation of european patent specification	Ref document number: 1589107 Country of ref document: EP

Date

Code

Title

Description

2010-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1589107

Country of ref document: EP